Cdk9 and Brd4 regulate eukaryotic transcription by Decker, Tim-Michael
DISSERTATION ZUR ERLANGUNG DES DOKTORGRADES 
DER FAKULTÄT FÜR BIOLOGIE 
DER LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN 
 
 
Cdk9 and Brd4 regulate 
eukaryotic transcription  
 
 
 
 
 
 
 
 
 
 
 
TIM-MICHAEL DECKER 
 
April 2017 
 
 
 
Completed at the Helmholtz Center Munich 
German Research Center for Environment and Health (GmbH) 
Institute of Functional Epigenetics 
Department of Molecular Epigenetics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date of Submission:    19.04.2017     
 
First Examiner:      Prof. Dr. Dirk Eick 
Second Examiner:     Prof. Dr. Heinrich Leonhardt 
 
Date of oral examination:   12.12.2017 
 
 
 
 
Eidesstattliche Erklärung 
Ich versichere hiermit an Eides statt, dass die vorliegende Dissertation von mir selbst-
ständig und ohne unerlaubte Hilfe angefertigt ist . 
 
 
Erklärung 
Hiermit erkläre ich, dass die Dissertation nicht ganz oder in wesentlichen Teilen einer 
anderen Prüfungskommission vorgelegt worden ist. 
Ich erkläre weiter, dass ich mich anderweitig einer Doktorprüfung ohne Erfolg nicht 
unterzogen habe. 
 
 
 
München, im April 2017 
 
 
 
Tim-Michael Decker 
Summary  i 
 
I Summary 
The bromodomain protein Brd4 is an epigenetic reader and binds to acetylated histone 
tails. Brd4 activates transcription by recruiting the positive elongation factor P-TEFb. 
Small molecule inhibitor JQ1 competitively binds the bromodomains of Brd4 and dis-
places the protein from acetylated histones. However, it remains unclear whether genes 
targeted by JQ1 are mainly regulated by Brd4 or by other bromodomain proteins such 
as Brd2 and Brd3. In this work, I describe anti-proliferative dominant-negative Brd4 
mutants that compete with the function of distinct Brd4 domains. I used these Brd4 mu-
tants to compare the Brd4-specific transcriptome with the transcriptome of JQ1-treated 
cells. I found that most JQ1-regulated genes are also regulated by dominant-negative 
Brd4 mutants, including the mutant that competes with the P-TEFb recruitment func-
tion of Brd4. My results suggest that Brd4 mediates most of the inhibitory effects of JQ1 
and that the major function of Brd4 in this process is the recruitment of P-TEFb. 
The kinase subunit of P-TEFb, Cdk9, is a well-known regulator of transcription 
elongation. Recruitment and activation of Cdk9 by Brd4 or other factors, is crucial for 
the release of promoter proximal paused RNA polymerase II. To characterize the role of 
Cdk9 in this process in more detail, I used a CRISPR/Cas9 engineered cell system for 
fast and efficient inhibition of Cdk9 kinase activity. Inhibition of this analog-sensitive 
Cdk9 decreased cell proliferation and reduced phosphorylation levels of RNA polymer-
ase II C-terminal domain, in particular at Serine 2 residues. Nascent transcriptome 
analysis revealed that Cdk9 indeed facilitates efficient pause release. Strikingly, I further 
observed that pausing delimits the rate of transcription initiation, indicating that pause 
release activates genes by increasing the number of transcribing polymerases per time. 
Thus, Brd4 and Cdk9 together regulate transcription of RNA polymerase II by facilitat-
ing efficient pause release. 
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1 Introduction 
1.1 Chromatin 
The deoxyribonucleic acid (DNA) of eukaryotes is not naked. Instead it is well orga-
nized in a higher order structure that heavily influences the activity of genes. Many 
components are involved in this structuring process. DNA, histones, and non-histone 
proteins contribute to build up the structure that allows a complex regulation of gene 
activity known as chromatin. There are two different ground states of chromatin: eu-
chromatin and heterochromatin. Euchromatin is decondensed and typically comprises 
active genes. Heterochromating is condensed and genes located within heterochromatic 
chromatin are generally repressed. Chromatin states and thus gene activity is influenced 
by many factors, including DNA methylation and histone modifications. These are so-
called epigenetic mechanisms that stabilize gene expression programs in addition to the 
DNA template (Allis & Jenuwein 2016). 
1.1.1 Chromatin structure 
The first step of chromatin assembly involves the incorporation of nucleosomes. Nucle-
osomes are the basic unit of eukaryotic chromatin structure and are built by histone 
proteins. Canonical histones are comprised of histone 2A, histone 2B, histone 3, histone 
4 and the so-called linker histone 1 (H2A, H2B, H3, H4, H1). Two molecules of each 
H2A, H2B, H3 and H4 make up a core nucleosome, also called histone octamer. 
147 base pairs (bp) of DNA is wound around the histone octamer and ‘sealed’ by H1 
(Allis & Jenuwein 2016; Luger et al. 1997; Venkatesh & Workman 2015). Consecutive 
incorporation of nucleosomes leads to the ‘beads-on-a-string’ structure as it is seen for 
condensed chromatin in the electron microscope (Olins & Olins 1974). The DNA that 
connects nucleosomes is called ‘linker DNA’ and nucleosomes repeat at an interval of 
~200 bp. Incorporation of histones is facilitated by designated remodeling enzymes. 
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Chromatin remodelers are also responsible for the correct spacing of the nucleosomes 
and contribute to the overall chromatin dynamics. Chromatin dynamics includes the 
dynamic addition, removal and exchange of nucleosomes or histones. Importantly, spe-
cial histone variants are incorporated, e.g. at centromers or sites of DNA damage. Fur-
thermore, structural analysis of histones revealed that the amino (N)-terminal tails of 
histones are not part of the histone fold but are protruding the core of the nucleosome. 
This makes the histone tails accessible for a multitude of binding and modifying factors 
(for review see Venkatesh & Workman, 2015). 
1.1.2 Post-translational histone modifications 
Similar to many other proteins, histones are post-translationally modified. Most modifi-
cations are described for the N-terminal histone tails, although histones can be modified 
in the histone fold as well (reviewed in Lawrence et al. 2017). Histone modifying en-
zymes (‘writers’) include acetyltransferases, methyltransferases, kinases, and ubiquiti-
nases. Enzymes that remove such modifications (‘erasers’) include deacetylases, 
demethylases, phosphatases, and deubiquitinases (Marmorstein & Zhou 2014). A third 
group of proteins called ‘readers’ has become the focus of research only recently. His-
tone readers recognize and interpret specific histone modifications or their absence. 
Thereby they convey particular signals associated with those modifications to chroma-
tin-related processes such as transcription or chromatin structure. The idea that histone 
modifications can arise in a particular pattern that triggers downstream events is also 
known as the ‘histone code’ (Strahl & Allis 2000). Overall the histone code defines not 
only the accessibility of chromatin but also the activity of associated genes (Figure 1-1). 
 Acetylation of histones has been extensively studied over the last two decades. After 
the first histone acetyltransferase (HAT) and histone deacetylase (HDAC) were identi-
fied in 1996 (Brownell et al. 1996; Taunton et al. 1996), over 20 HATs and HDACs have 
been studied in detail (Verdin & Ott 2015). Proteins can bind acetylated Lysines of his-
tones using a conserved domain called bromodomain (Dhalluin et al. 1999; Yap & Zhou 
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2010). Bromodomains are found in many chromatin-related proteins including HATs, 
chromatin remodelers, nuclear scaffolding proteins, and the bromodomain and extra-
terminal domain (BET) protein family (see chapter 1.2.4). Histone acetylation inhibits 
the formation of secondary and tertiary structures in the core nucleosomes, thereby de-
condensing chromatin structure and recruiting histone readers (Verdin & Ott 2015). 
Hence, the complex action of writers and erasers of histone modifications regulate the 
accessibility of chromatin for transcription factors and other transcriptional co-
activators. 
 
 
Figure 1-1 | Acetylation of histone tails induces chromatin remodeling to activate tran-
scription. Histone marks are removed by eraser enzymes. Acetylation marks (Ac) are removed 
by histone deacetylases which leads to compaction of chromatin and results in transcriptional 
repression. Histone acetyltransferases are writers that acetylate histone tails to decondense 
chromatin and activate transcription (modified from Verdin & Ott, 2015).  
1.2 Transcription of RNA Polymerase II 
Histone modifications substantially contribute to gene activation and transcription of 
ribonucleic acid (RNA). Bacteria have developed only one enzyme that synthesizes 
RNA. This single RNA polymerase is composed of four catalytic subunits that are regu-
lated by another subunit known as sigma. Different sigma factors bind to distinct pro-
moter sequences and thereby regulate the transcription of unique sets of genes (Clancy 
2008). In eukaryotes, three different RNA polymerases (Pol I, Pol II and Pol III) tran-
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scribe RNA from the genomic DNA template (Roeder & Rutter 1969). Structurally, all 
three polymerases contain a ten-subunit catalytic core. However, Pol I, Pol II, and 
Pol III further contain other subcomplexes adding up to 14, 12, and 17 subunits in total, 
respectively (Vannini & Cramer 2012). 
The three RNA polymerases characteristically differ in their gene targets and tran-
scription initiation pathways, enhancing the complexity of gene regulation. Pol I tran-
scribes the 35S precursor of the 28S, 18S and 5.8S ribosomal RNAs (rRNAs) 
(Viktorovskaya & Schneider 2015). Pol II transcribes messenger RNAs (mRNAs) from 
all protein-coding genes and most regulatory, non-coding RNAs (Cooper 2000; Deniz & 
Erman 2016). Pol III synthesizes transfer RNAs (tRNAs), cellular 5S rRNA and some 
other short RNAs like U6 small nuclear RNA (snRNA) (Arimbasseri & Maraia 2016). In 
addition to mRNA synthesis Pol II regulates the whole set of co-transcriptional RNA-
processing events and is involved in chromatin-linked interactions (Saldi et al. 2016). 
Below, the mechanism of Pol II transcription will be elucidated in more detail. 
1.2.1 Transcription cycle of RNA polymerase II 
Transcription of Pol II dependent genes can be grouped into three major stages: initia-
tion, elongation and termination. The transcriptional machinery is composed of a mul-
titude of enzymes and protein complexes including general transcriptions factors 
(GTFs: TFIIA, TFIIB, TFIID, TFIIE, TFIIF, TFIIH), Pol II, the Mediator and several 
other co-activators, co-repressors, chromatin modifiers and remodelers (Gupta et al. 
2016; Thomas & Chiang 2006). 
 
Preinitiation 
Transcription begins with the formation of the Preinitiation Complex (PIC), which itself 
is a stepwise process (Figure 1-2A-B). First TFIID containing the TATA-box binding 
protein (TBP) binds to the core promoter (Davison et al. 1983; Sawadogo & Roeder 
1985). After the sequential entry of TFIIA and TFIIB that stabilize TFIID binding to the 
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promoter (Buratowski et al. 1989), Pol II and TFIIF are recruited. At last, TFIIE enters 
the PIC followed by TFIIH. Interestingly, an alternative model to this sequential PIC 
assembly pathway was described as the Pol II holoenzyme pathway. The Pol II holoen-
zyme pathway suggests that upon TFIID binding to the promoter, Pol II is recruited as a 
preassembled holoenzyme complex, containing a subset of GTFs and other proteins that 
are involved in chromatin remodeling, DNA repair and mRNA processing (Thomas & 
Chiang 2006). Both pathways may exist in vivo and depending on promoter context and 
specific signaling molecules either pathway could be used.  
In vivo the initiation complex is further stabilized by the coactivator complex Media-
tor. The Mediator achieves this by cooperating with the GTFs TFIIB, TFIID and TFIIH 
(Plaschka et al. 2016). Given its multisubunit structure that makes various contacts with 
the polymerase, the Mediator serves as a scaffold to bridge transcription factors to Pol II. 
In yeast, conditional dissociation of a Mediator subcomplex lead to reduced global RNA 
levels (Linder et al. 2006; Thompson et al. 1993). This indicates that the Mediator sub-
stantially contributes to well-regulated transcription in vivo by increasing efficiency of 
PIC assembly.  
The processes presented above were initially described based on biochemical studies. 
Recent advances in structural biology have confirmed and refined many of these mod-
els. Especially the advances in 3D electron microscopy have enabled researchers to un-
ravel the composition of large complexes and determine the exact points of contact 
between different subcomplexes (Hantsche & Cramer 2016). Once it is assembled, the 
PIC adopts a “closed” state, unable to initiate transcription. To open the DNA up about 
11 to 15 bp around the transcriptional start site (TSS) the XPB helicase subunit of TFIIH 
induces a torsional strain, positioning single-stranded DNA to the active site of Pol II. 
Pol II is now prepared to enter elongation and transcribe throughout a gene without 
dissociating from the DNA template (Gupta et al. 2016).  
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Initiation 
When the DNA template is melted, the polymerase starts to produce the RNA tran-
script. However, this early transcription is unstable and often results in abortive tran-
scription. Once the transcript has reached a length of about 5 nucleotides (nt) the 
polymerase can escape the promoter and enter the elongation phase. Interestingly, 
phosphorylation of the carboxy (C)-terminal domain (CTD) of Pol II by cyclin depend-
ent kinase 7 (Cdk7), a subunit of TFIIH, prevents direct binding of the Mediator to 
Pol II (Søgaard & Svejstrup 2007). After Pol II has escaped from the promoter TFIID, 
TFIIA, TFIIH, TFIIE and Mediator were described to form a scaffold for a re-initiation 
complex that allows rapid recruitment of Pol II and assembly of another functional PIC 
(Yudkovsky et al. 2000).  
 
Early elongation 
While the RNA chain is being elongated via the so-called nucleotide addition cycle (for 
review see Hantsche & Cramer, 2016), the transcript reaches a critical length of 17-25 nt. 
At this stage, the nascent transcript needs to be protected from degradation by nuclear 
5’ -> 3’ exoribonucleases like Xrn2. This is achieved by addition of a 5’ cap structure. 
Recruitment of the capping machinery again is dependent on CTD phosphorylation 
(Figure 1-2C; see chapters 1.2.2 and 1.2.3). In eukaryotes the 5’ guanine-N7 methyl cap 
is the first modification of nascent pre-mRNA. Capping occurs in three sequential en-
zymatic reactions of which the metazoan Capping Enzyme catalyzes the first two: (1) 
RNA triphosphatase cleaves the 5’ triphosphate of the pre-mRNA. (2) The resulting di-
phosphate end is capped with guanosine monophosphate (GMP) by RNA guan-
ylyltransferase to form 5’ guanylylated-RNAs. (3) RNA guanine-N7 methyltransferase 
transfers a methyl group to the N7 position of the terminal guanine base to complete the 
synthesis of cap (for review see Ghosh & Lima, 2010). 
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Figure 1-2 | Transcription cycle of RNA polymerase II. RNAPII with an hypo-phosphorylated 
CTD (A) is recruited to the pre-initiation complex (B). At the initiation phase Ser5 and Ser7 are 
phosphorylated (C). Ser5-P induces release of the pre-initiation complex as well as capping of 
the 5’ mRNA end. Pol II pausing at the promoter proximal region is generated by DSIF and 
NELF. Release from the elongation block is facilitated by the kinase activity of P-TEFb, consist-
ing of Cdk9 and CyclinT1. Cdk9 phosphorylates Ser-2, DSIF, and NELF, causing the dissocia-
tion of NELF and conversion of DSIF from a negative to a positive elongation factor (D). 
Throughout elongation Thr4 and Tyr1 are also phosphorylated, as is Ser2 at increasing levels. 
(E). When reaching termination of transcription the phosphorylations of Tyr1, Thr4 (in yeast), S5 
and S7 are removed by phosphatases (F). To enter a new cycle all remaining CTD phosphoryla-
tions must be removed again. 
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In higher eukaryotes including Drosophila and mammals, the elongating polymerase 
is stalled 20-80 bp downstream of the TSS. This rate-limiting step in early elongation is 
often referred to as promoter proximal pausing. Paused Pol II has been extensively stud-
ied on the Hsp70 and c-Myc loci in Drosophila and human cell lines, respectively 
(Bentley & Groudine 1986; Eick & Bornkamm 1986; Rougvie & Lis 1988). In C. elegans 
pausing levels are strongly reduced and yeast appears to lack pausing completely, sug-
gesting that promoter proximal pausing is exclusive for higher eukaryotes. Indeed, ap-
proximately 40%-46% and 70%-89% of active genes were identified as paused in 
mammalian and Drosophila cells, respectively (Kwak & Lis 2013). More recent studies 
observed Pol II pausing at 60%-95% of mammalian genes (Day et al. 2016; Jonkers et al. 
2014), suggesting that this regulatory mechanism is indeed crucial for expression of 
most mammalian genes. Although many active genes are paused, the degree of pausing 
varies dependent on cis-acting DNA elements, nucleosome occupancy, and certain 
elongation factors.  
Negative elongation factor (NELF) and DRB-sensitivity-inducing factor (DSIF, con-
sisting of subunits Spt4 and Spt5) are the main pausing factors that block Pol II from 
further elongation (Renner et al. 2001; Wu et al. 2003) (Figure 1-2D). NELF is a 5-
subunit complex and was reported to interact with RNA via its NELF-E subunit but also 
interacts with DSIF and Pol II (Yamaguchi et al. 1999). Interestingly, knockdown of 
NELF by RNAi reduced transcription rates of most genes (Amleh et al. 2009), indicating 
that pausing is not an inhibitory mechanism but a regulatory feature that allows stimu-
lation of transcription. Accordingly, paused Pol II was reported to keep promoters free 
from nucleosomes (Gilchrist et al. 2010). Thus, promoter proximal pausing is a com-
mon characteristic of highly regulated, active genes and contributes to keeping the pro-
moter accessible to transcription factors (reviewed in Jonkers & Lis, 2015). 
The elongation block is released after recruitment of positive transcription elonga-
tion factor b (P-TEFb) which is a heterodimer composed of cyclin-dependent kinase 9 
(Cdk9) and cyclin T1/T2 (Peng et al. 1998). Interestingly, the recruitment of P-TEFb 
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itself is highly regulated and can be facilitated e.g. by bromodomain protein 4 (Brd4) or 
orchestrated by the Super Elongation Complex (SEC) (see section 1.2.4). Cdk9 then 
phosphorylates NELF and the Spt5 subunit of DSIF (Fujinaga et al. 2004; Kim & Sharp 
2001). This causes NELF to dissociate and converts DSIF into a positive elongation fac-
tor (Yamada et al. 2006). Together these tightly regulated events lead to the release of 
the paused polymerase into productive elongation (Fowler et al. 2014). 
 
Productive elongation 
During elongation various coactivators are recruited to the transcription machinery to 
promote the ongoing transcription as well as cotranscriptional RNA processing events 
(Figure 1-2E). Pol II not only pauses in the promoter proximal region but also around 
exons (Jonkers et al. 2014), highlighting that splicing is a co-transcriptional event. Co-
transcriptional splicing is partly regulated by dynamic phosphorylations of the CTD. 
For example, recruitment of the U2AF65-Prp19 complex via phosphorylated CTD acti-
vated in vitro splicing (David et al. 2011). Accordingly, splicing defects and reduced re-
cruitment of U2AF65 and U2 snRNP were observed in a CTD mutant that cannot be 
phosphorylated on Ser2 (Gu et al. 2013). The Mediator is probably involved in recruit-
ing processing factors as well. Its Med23 subunit binds the splicing factors hnRNPL, 
SF3B, and Eval1, indicating a crosstalk between splicing and the Mediator. Besides spa-
tial coupling of processing factors to the site of transcription many other factors influ-
ence co-transcriptional splicing, including the elongation rate (reviewed in Saldi et al. 
2016). 
The transcription elongation rate, the velocity Pol II is producing RNA, increases af-
ter the first few kilobases (kb) from ~0.5 kb per minute to 2-5 kb per minute after 
~15 kb (Fuchs et al. 2014; Jonkers et al. 2014). However, elongation rates can vary, de-
pending on nucleosome occupancy or histone marks that restrict or promote the speed 
of the polymerase (Bintu et al. 2012). For example ubiquitinylation of histone H2B and 
trimethylation of H3 at Lys36 are found within the gene body, potentially influencing 
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the speed of transcription (reviewed in Venkatesh & Workman, 2015). Further studies 
describe a correlation between H3K79me2 and H4K20me1 with high elongation rates 
and gene- or sequence-related features such as gene length and low complexity DNA 
sequence (Fuchs et al. 2014; Jonkers et al. 2014; Veloso et al. 2014). Together, these find-
ings highlight the strong interdependence between histone marks and transcription 
elongation. 
 
Termination 
While transcriptional initiation is well characterized, less is known about the mecha-
nism of termination. In eukaryotes two models have been proposed to describe termina-
tion: the allosteric model and the torpedo model. When the polymerase arrives at a 
functional poly-adenylation (poly(A)) site multiple events such as the activity of cleav-
age and polyadenylation factors (CPAs) trigger the release of the RNA transcript and the 
polymerase (reviewed in Proudfoot, 2016) (Figure 1-2F). In the allosteric model, Pol II 
senses a poly(A) site. Following the association with CPAs this leads to conformational 
changes that eventually cause termination of transcription. Alternatively, the torpedo 
model suggests that Pol II keeps transcribing after cleavage of the nascent transcript. 
Then, the 5’-3’ exonuclease Xrn2 is recruited to the poly(A) site and starts degrading the 
uncapped 5’ end of the Pol II associated transcript. When Xrn2 reaches the polymerase, 
the release of Pol II from the DNA template is triggered. While the detailed mechanism 
of this process is currently unclear, several regulatory factors of transcriptional termina-
tion have been identified. 
 One event that influences termination and selection among multiple poly(A) sites is 
Pol II pausing. By slowing down the Pol II elongation complex, CPA association with 
the poly(A) site and 3’ processing are enhanced. Recognition of a poly(A) site alone can 
lead to pausing effects, conformational changes and increased termination 
(Kazerouninia et al. 2010; H. Zhang et al. 2015). Pausing can also be induced by for-
mation of R loops, RNA:DNA hybrids that are established when the nascent transcript 
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hybridizes with the antisense DNA strand outside of the elongation complex (reviewed 
in Skourti-Stathaki & Proudfoot, 2014). Accumulating R loops can result in single- and 
double-strand breaks that are potentially mutagenic (Aguilera & García-Muse 2012). 
Therefore, R loops need to be resolved. In mammals Senataxin is not only required to 
resolve R loops but also promotes efficient termination (Skourti-Stathaki et al. 2011). 
Interestingly, Senataxin is recruited via SMN that recognizes a specific methylation 
mark on the Pol II CTD (Zhao et al. 2015). In summary, these events elucidate the com-
plex regulation of transcriptional termination. 
1.2.2 C-terminal domain of RNA Pol II (CTD) 
RNA polymerase II is uniquely equipped with a repetitive structure at the C-terminus of 
the large subunit Rpb1 (Saldi et al. 2016). This C-terminal domain (CTD) consists of 
tandem heptad repeats with the consensus sequence of Tyrosine-Serine-Proline-
Threonine-Serine-Proline-Serine (Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-Ser7). The CTD of 
budding yeast has a length of 26 repeats of which most repeats harbor the consensus 
sequence. Mammals have developed a longer, more diverse CTD with 52 repeats and 
several repeats in the proximal part of the CTD that vary from the consensus sequence. 
Interestingly, the CTD is dynamically modified throughout the transcription cycle. 
Phosphorylation of the Serine residues is the best-studied modification but also acetyla-
tion, methylation, ubiquitinylation and Proline-isomerization have been described. Giv-
en the complexity of potential modification patterns, the CTD is regarded as a binding 
platform for a multitude of transcription-associated factors. This forms the CTD into a 
‘switch panel’ that controls the whole process of transcription. 
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1.2.3 Kinases phosphorylate the CTD throughout the transcription 
cycle 
Cyclin-dependent kinases (Cdks) can be divided into two major groups. The activity of 
Cdks 1, 2, 3, 4, 5, and 6 is tightly connected to regulation of the cell cycle and cell devi-
sion. The second group is involved in regulation of transcription and includes Cdks 7, 8, 
9, 12, and 13 whereas Cdk10 and Cdk11 presumably contribute to both processes 
(Paparidis et al. 2017). As described below, all transcription-related Cdks have been re-
ported as CTD kinases (Eick & Geyer 2013). Recently, it was suggested that Cdk11 
phosphorylates the CTD as well (Pak et al. 2015). However, according to a previous in 
vitro study Casein Kinase 2 (CK2) but not Cdk11 facilitates CTD phosphorylation and 
Cdk11 is in fact a CK2 target (Trembley et al. 2003). 
The dynamic modification patterns of the CTD throughout the transcription cycle 
have been revealed, using phospho-specific antibodies in chromatin immunoprecipita-
tion (ChIP) and native elongating transcript sequencing (NET-seq) analyses (reviewed 
in Eick & Geyer 2013; Zaborowska et al. 2016). When Pol II enters the pre-inititation 
complex its CTD is hypo-phosphorylated, a state known as IIa form (Lu et al. 1991) 
(Figure 1-2A-B). The first modifications of the CTD are placed at the 5’ end of the gene 
during the initiation phase. Here, Cdk7, a subunit of the general transcription factor 
TFIIH, phosphorylates Ser5 and Ser7 (Akhtar et al. 2009; Glover-Cutter et al. 2009; Kim 
et al. 2009; Lu et al. 1992; Rodriguez et al. 2000) (Figure 1-2C). The intact PIC and pres-
ence of the Mediator are prerequisites for phosphorylation of Ser7 (Ser7-P) by Cdk7 
(Boeing et al. 2010). The same study suggests that additional, so far unknown kinases 
phosphorylate Ser7 in coding regions. Functionally, Ser7-P supposedly regulates tran-
scription of small nuclear RNAs (Chapman et al. 2007; Egloff et al. 2007). Phosphoryla-
tion of Ser5 is required for successful release of Pol II from the PIC as well as for 
recruiting the 5’ end capping enzyme which interacts with Ser5-P and Tyr1 (Cho et al. 
1997; Ghosh et al. 2011; McCracken et al. 1997; Søgaard & Svejstrup 2007). Tyr1-P is 
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mostly found at the beginnings of coding genes, where it is also associated with anti-
sense promoter transcription and active enhancers (Descostes et al. 2014). The only ki-
nase with reported Tyr1-P activity so far is c-Abl (Baskaran et al. 1999), although the 
role of c-Abl as a CTD kinase remains unclear (Zaborowska et al. 2016). Together, the 
dynamic phosphorylations of the CTD are shifting Pol II into the hyperphosphorylated 
IIo form, a state that marks the polymerase as actively transcribing. 
 The level of Ser5-P gradually drops during elongation caused by phosphatase activity 
of RPAP2 and Ssu72 (Egloff et al. 2012; Krishnamurthy et al. 2004; Wani et al. 2014). 
Ssu72 dephosphorylates Ser7-P as well, and is essential for efficient termination (Zhang 
et al. 2012). Ser2 gets phosphorylated by Cdk9 (Cho et al. 2001; Marshall et al. 1996; 
Wood & Shilatifard 2006) which is regarded as a requirement for efficient elongation 
(Figure 1-2D). In vitro studies on CTD peptides point to a role of Cdk9 as a Ser5 kinase 
and suggest that Ser5-P but not Ser2-P marks the polymerase for efficient pause release 
and Ser7-P primes the CTD for this modification (Czudnochowski et al. 2012). Interest-
ingly, inhibition of Cdk9 with the chemical inhibitor Flavopiridol caused increased 
promoter proximal pausing of Pol II, indicating that efficient pause release is blocked 
upon inhibition of Cdk9 (Jonkers et al. 2014). However, Flavopiridol is known to inhibit 
other kinases as well, including Cdk12 and Cdk13 that both have been reported to be 
Ser2 kinases (Bartkowiak et al. 2010). Conversely, the histone reader Brd4 was recently 
described to possess Ser2 kinase activity, in addition to its well-known role in P-TEFb 
activation (Devaiah et al. 2012). While the roles of Brd4 and Cdk13 as Ser2 kinases need 
to be further elucidated, several studies have analyzed the function of Cdk12 in more 
detail. 
The majority of Cdk9 occupies the 5’ region of a gene (Ghamari et al. 2013; Lin et al. 
2011), but Cdk12 is mostly found at the 3’ end (Bartkowiak et al. 2010). This suggests a 
mechanism in which Cdk9 is placing Ser2-P marks early in transcription, whereas 
Cdk12 is the major Ser2 kinase towards the 3’ end of genes (reviewed in Bowman & 
Kelly, 2014). Nonetheless, two recent studies reported a role for Cdk9 in transcription 
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termination, hence at the 3’ end of genes. Here Cdk9 possibly regulates Pol II pausing at 
the poly(A) site (Laitem et al. 2015) or as a regulatory kinase of Xrn2 (Sansó et al. 2016) 
(see “Termination” paragraph in chapter 1.2.1). Another CTD phosphorylation mark, 
Thr4-P, is highest at 3’ ends and Polo-like kinase 3 (Plk3) is presumably the responsible 
kinase in human cells (Hintermair et al. 2012). Importantly, the CTD gets dephosphory-
lated to allow processive termination and recycling of Pol II for another transcription 
cycle (Cho et al. 2001; Lin et al. 2002). Together, these dynamic CTD modifications are 
connected to the different stages of the transcription cycle and Pol II activity. 
1.2.4 Brd4 recruits Cdk9 to sites of active transcription 
Brd4 is a member of the mammalian bromo and extra-terminal domain protein family 
(BET), which further comprises Brd2, Brd3, and testis-specific Brdt (reviewed in 
Taniguchi, 2016) (Figure 1-3A). The characteristic domains of mammalian BET pro-
teins are conserved in orthologues including Drosophila fs(1)h and Saccharomyces cere-
visiae Bdf1 and Bdf2. All four mammalian BET proteins feature two N-terminal 
bromodomains (BD1 and BD2). Bromodomains are common in chromatin-associated 
proteins and proteins equipped with bromodomains usually bind acetylated histone 
tails. This has also been observed for Brd4 (Dey et al. 2003). Interestingly, the histone 
binding specificity amongst the two bromodomains of Brd4 differs and is more similar 
for a single bromodomain of different BET proteins (Filippakopoulos et al. 2012). This 
is in line with the phylogenic representation of human bromodomains, where each BD1 
and BD2 of the different BET proteins are grouped together (G. Zhang et al. 2015) 
(Figure 1-3A). 
In addition to bromodomains, other Brd4 domains are similar important for sup-
porting the function of this histone reader. Two p53 interacting domains were de-
scribed, located in between BD2 and ET. Interestingly both domains, BID and PDID, 
could pull down p53 independently and have been proposed to provide regulatory func-
tions to Brd4, triggered by phosphorylation by Casein Kinase II (Wu et al. 2013). 
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Figure 1-3 | The human BET protein family. (A) Domain structure of the human BET protein 
family. All BET members feature two tandem bromodomains (BD1 and BD2) at the N-terminus 
and an extraterminal (ET) domain. Brd4 harbors a P-TEFb interacting domain (PID) which is 
conserved in Brdt. The asterisk (*) marks the length of a second isoform Brd4 short (Brd4S) 
which lacks the C-terminal stretch from 723-1362. (B) In the phylogenic tree of human bromo-
domains BD1 (yellow) and BD2 (orange) are grouped together although they are derived from 
different BET proteins (modified from Zhang et al. 2015a).  
 
The ET domain supposedly regulates chromatin modifying enzymes and was report-
ed to bind the argenine demethylase JMJD6 and the lysine methyltransferase NSD3 (Liu 
et al. 2013; Rahman et al. 2011). Additionally, interactions of the ET domain with nucle-
osome remodelers SWI/SNF and CHD4 were described (Rahman et al. 2011). Brd4 is 
unique for a P-TEFb-interacting domain (PID) at its C-terminus, where it binds the ki-
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nase subunit Cdk9. This domain is highly conserved in human testis-specific Brdt and 
Drosophila fs(1)h (Bisgrove et al. 2007). The kinase activity of Cdk9 is essential for tran-
scriptional elongation of most mammalian genes (see chapters 1.2.1 and 1.2.3). Hence, 
the current model depicts Brd4 as a chromatin reader that binds to active chromatin via 
acetylated histone marks using its N-terminal bromodomains. The PID domain can 
then recruite and activate P-TEFb from its inactive complex that further comprises 
Hexim1/2, Larp7, MePCE and 7SK snRNA, which is also known as 7SK small nuclear 
ribonucleoprotein (snRNP) (Yang et al. 2005). Importantly, only the activated P-TEFb 
can join the transcriptional machinery and release Pol II from the elongation block 
(reviewed in dos Santos Paparidis et al. 2016) (Figure 1-2D). 
Brd4 is the only somatic BET member capable of directly binding to Cdk9, since the 
PID domain is not present in the short isoform of Brd4 (Brd4-s), Brd2 or Brd3. Howev-
er, BD2 of Brd4 might also bind P-TEFb via acetylated CyclinT1, suggesting a 2-step 
mechanism of P-TEFb activation by Brd4 that also involves the BD2 domain (Schröder 
et al. 2012). Interactions between P-TEFb and BD2 of BET proteins other than Brd4 
have not been reported so far. Together, this highlights the importance of the PID for 
Brd4 function as it directly connects Brd4 to transcriptional regulation. 
Given its role as P-TEFb activator, Brd4 facilitates transcription not only at coding 
genes but also at enhancers (Kanno et al. 2014; Liu et al. 2013). In fact, Brd4 has been 
described as a key factor characteristic for so-called super enhancers (Hnisz et al. 2013; 
Lovén et al. 2013). These enhancers are typically highly active and promote transcrip-
tion of genes that define cell identity. Genome-wide ChIP-seq studies demonstrate co-
occupancy of Mediator and Brd4 at super enhancers, highlighting the connection be-
tween the two transcriptional regulators that were co-purified previously (Jiang et al. 
1998; Lovén et al. 2013). High Brd4 occupancy at enhancers suggests that Brd4 activates 
transcription of enhancer-associated genes. Indeed, inhibition of Brd4 with a small mol-
ecule drug resulted in transcriptional elongation defects that mainly affected genes regu-
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lated by super-enhancers (Lovén et al. 2013). In summary, Brd4 is associated with the 
transcription of most active genes and is therefore a master regular of transcription. 
1.2.5 Brd4 and cancer 
In the year 2010 two small molecule inhibitors were developed that specifically target 
the bromodomains of BET proteins. These two inhibitors, JQ1 and I-BET, were the first 
of a new drug class called BET inhibitors (Filippakopoulos et al. 2010; Nicodeme et al. 
2010). Importantly, both JQ1 and I-BET target the bromodomains of all BET family 
members including Brd2, Brd3, Brd4, and Brdt. JQ1, like all other BET inhibitors, binds 
to the histone-acetyl binding pocket of the bromodomains thereby blocking the binding 
to acetylated histone tails. Constantly, improved BET inhibitors are reported. For exam-
ple, the novel inhibitor RVX-297 demonstrates differential binding to BD1 and BD2 
domains of BET proteins, selectively targeting BD2 (Kharenko et al. 2016). Together, 
BET-inhibitors are a powerful tool to study Brd4 function. 
 Inhibition of Brd4 with JQ1 results in its eviction from active chromatin. According-
ly, Brd4 occupancy decreases at many genes after treating human cell lines with JQ1. At 
genes where Brd4 is the major recruiting factor of P-TEFb, this resulted in reduced gene 
expression, as described for the c-Myc oncogene (Delmore et al. 2011; Mertz et al. 2011). 
JQ1 lead to broad eviction of Brd4 from chromatin in B-cell tumors and repressed genes 
were enriched for c-Myc and E2F targets (Donato et al. 2016). Similar results were re-
ported for I-BET, which inhibited transcription of BCL2, c-Myc and CDK6 in promyelo-
cytic leukemia cells (Dawson et al. 2011). It was known before that Brd4 has an 
implication in some forms of cancer, as the Brd4-NUT fusion oncogene was identified 
in aggressive forms of carcinomas (French et al. 2003). Brd4 further promotes expres-
sion of viral oncogenes from human papilloma virus (Yan et al. 2010). With these find-
ings, it was recognized that BET-inhibitors very effectively decrease expression of 
several oncogenes along with anti-proliferative effects when tested in human cancer cell 
lines. Consequently, Brd4 was identified as a promising target for cancer therapy. 
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 The therapeutic potential of Brd4 inhibition was rapidly evaluated. Screening of sev-
eral cell lines for JQ1 sensitivity indicated that lymphoid and myeloid tumors are espe-
cially responsive to the inhibitor in terms of anti-proliferative effects (Mertz et al. 2011). 
This was confirmed in animal models for acute myeloid leukemia (AML) and multiple 
myeloma (MML), where JQ1 efficiently reduced tumor load (Delmore et al. 2011; 
Zuber, et al. 2011). Numerous studies have followed and demonstrated that a wide range 
of tumors, including breast cancer and prostate cancer, can potentially be drugged with 
BET inhibitors (Asangani et al. 2014; Shu et al. 2016). Based on the results obtained 
from cell culture experiments and animal studies, early excitement arose about this new 
drug class. Several ongoing clinical trials are evaluating the efficiency and safety of BET 
inhibitors for human patients (Andrieu et al. 2016). In a recent report the administered 
drug OTX015 showed promising anti-tumor activity in patients with advanced stages of 
NUT midline carcinoma (Stathis et al. 2016). However, more clinical trials will provide 
major insights whether BET inhibitors are indeed applicable in therapy of human cancer 
patients. 
1.3 Scope of this thesis 
Brd4 and Cdk9 together are key regulators of transcription elongation. Elongation is 
tightly controlled within the transcription cycle of RNA Pol II as illustrated by the phe-
nomenon of promoter proximal pausing. Furthermore, both proteins have implications 
in the development and maintenance of human cancers. This has led to the develop-
ment of specific inhibitors of Brd4 and Cdk9, most famously JQ1 and Flavopiridol, re-
spectively. Although these inhibitors have provided many insights into the function of 
the two proteins, their specificity is limited. Is Brd4 indeed the protein that mediates the 
anti-tumor effects of JQ1? Which target genes are specifically regulated by Brd4? Do 
distinct domains of Brd4 have differential downstream effects? What is the impact of the 
Brd4-Cdk9 interaction on global gene regulation? Which genes depend on Cdk9 activity 
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for processive transcription? These questions shall be answered within the scope of this 
thesis. The aim of this thesis is to shed light on (i) the specificity of JQ1 for targeting 
Brd4, (ii) the role of distinct Brd4 domains on global transcription regulation, (iii) the 
role of Brd4 as Cdk9-recruiting protein, and (iv) the role of Cdk9 in the synthesis of 
nascent transcripts.  
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2 Results 
2.1 Establishment of an inducible expression system for Brd4 
mutants 
BET inhibitor JQ1 is not specific for a single BET family member. So far this applies to 
all other available BET inhibitors as well, restricting their use to inhibit only one par-
ticular BET protein. However, many studies use JQ1 to study Brd4 function, based on 
the assumption that Brd4 is the main target of JQ1. Furthermore, JQ1 solely inhibits the 
bromodomain function of BET proteins. Any conclusions about other Brd4 domains 
drawn from JQ1 studies are therefore likely based on secondary effects. Due to these 
limitations of JQ1, I developed an alternative strategy to inhibit Brd4. 
To block the function of Brd4 in a domain-specific way, I constructed dominant-
negative mutants. To this end, full length Brd4 was divided into 9 overlapping fragments 
(f1-f9) of about 200 amino acids (aa) in length (Figure 2-1A). The HA-tagged constructs 
were cloned into the pRTS vector, which contains a bi-directional promoter allowing 
simultaneous expression of the Brd4 fragment and eGFP (Bornkamm et al. 2005). eGFP 
was used as a reporter for efficient induction. Vectors were stably transfected into Bur-
kitt lymphoma Raji cells, because this cell line was reported to be highly sensitive to JQ1 
(Mertz et al. 2011), suggesting that Raji cells are dependent on functional Brd4. Positive-
ly transfected cells were selected with hygromycin B and expression was induced by 
doxycycline (dox). Dox levels were carefully titrated to avoid toxic effects on the cells. 
Western analysis revealed that all Brd4 fragments f1-f9 were properly expressed, al-
though at different levels (Figure 2-1B). Full-length Brd4 (Brd4-HA) and f7 yielded low 
signals compared to f1, f2, f4, f8 and f9 with intermediate and f3, f5 and f6 with high 
levels of expression. No HA signal was detected in cells transfected with a luciferase-
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expressing construct (Raji-luc), which served as a control. Together, this repository of 
inducible Brd4 fragments allowed screening for dominant-negative mutants. 
 
 
Figure 2-1 | Expression system for Brd4 mutants. (A) Schematic structure of recombinant full-
length human Brd4 protein (Brd4-HA) and Brd4 fragments f1-f9. BD1/2 = bromodomain 1/2, 
ET = extra-terminal domain, PID = P-TEFb-interacting domain, HA = hemagglutinin tag, NLS = 
nuclear localization signal. (B) Expression levels of HA-tagged Brd4 mutants, assessed via 
Western analysis of the HA tag. α-Tubulin served as loading control. Samples were diluted with 
loading buffer prior to loading to visualize all signals on a single membrane (dilution ratios: 
lanes 2 and 9, 1:1; lanes 1, 3, 4, 6, 10 and 11, 1:10; lanes 5, 7 and 8, 1:20). Raji-luc cells ex-
pressed a non-tagged luciferase and served as negative control. 
2.2 Expression of Brd4 fragments inhibits cell proliferation 
I next investigated if overexpression of specific Brd4 domains can inhibit cell prolifera-
tion. For this purpose, I screened all cloned Brd4 constructs for a dominant-negative 
phenotype using proliferation assays. After induction of the Brd4 constructs, cell prolif-
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eration was monitored for 8 days. Two days after induction I consistently detected that 
proliferation rates were (i) substantially reduced for cells expressing Brd4 fragments f3, 
f5, f9, (ii) intermediately reduced for f4 and f6, and (iii) not affected in the control cell 
line Raji-luc or other Brd4 fragments (Figure 2-2).  
 
 
Figure 2-2 | Proliferation assay Brd4 mutants. Living cell numbers (log scale) of induced 
(25 ng/ml doxycycline, green) vs. non-induced (grey) cells were plotted against time. Induced 
cells expressed either luciferase (Raji-luc, negative control), Brd4 fragments f1 - f9, or recombi-
nant full-length Brd4 (Brd4-HA). For each condition three biological replicates were analyzed, 
except Brd4-HA, for which I obtained only one inducible clone.  
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Figure 2-3 | Induction of Brd4 mutants used in the proliferation assay. Ratios of induced 
cells (green) were assessed by measuring GFP reporter signals using flow cytometry, as a con-
trol for the proliferation assay on day 8 (Figure 2-2). Uninduced Raji f2 cells served as negative 
control (grey). For most replicates induction levels of ~90% were measured, with the exception 
of f4 E1, which was GFP negative, suggesting a selection of a non-inducible subclone. 
 
Proliferation rates were analyzed in three biological replicates. Here mutant f4 
showed inconsistent proliferation defects, because for replicate f4 E1 no defect was ob-
served. To verify efficient induction of the constructs in all cells, a prerequisite for dom-
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inant-negative inhibition, I measured GFP reporter signals on day 8 via flow cytometry 
and found induction rates of ~ 90% for most samples (Figure 2-3). However, f4-E1 was 
not inducible on day 8 indicating that the dominant-negative conditions selected for a 
non-inducible subpopulation in this replicate. Notably, I could confirm the dominant-
negative phenotype of Brd4 mutants in the non-small cell lung carcinoma cell line 
H1299 (Figure 2-4) 
 
Figure 2-4 | Proliferation assay of dominant-negative Brd4 mutants in H1299 cells. Prolifer-
ation of H1299 cells that express Brd4 constructs or luciferase (control) was measured using the 
XCelligence system (Roche). Expression of the recombinant proteins was induced via 1 µg/ml 
doxycycline 24 h after seeding of the cells. The cell index of induced (green) and non-induced 
(red) cells was measured for additional 48 h and plotted against time. Error bars: standard de-
viation, n=2. 
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Unexpectedly, expression of f3 comprising BD2 strongly inhibited cell proliferation 
whereas f1 comprising BD1 did not. I constructed a Brd4 f-BD1 mutant (54-168 aa of 
full length Brd4) to test whether overexpression of the first bromodomain alone will 
cause proliferation defects comparable to other dominant-negative mutants. Indeed, 
expression of f-BD1 caused substantial growth defects in well-induced cells (Figure 2-5), 
indicating that the N-terminal or C-terminal regions that flank BD1 in mutant f1 sup-
press the dominant-negative activity of BD1 overexpression. This is consistent with 
crystal structures of Brd4 suggesting that the 20 residues preceding BD1 can loop back-
wards and block the acetylated lysine recognition site (Vollmuth et al. 2009). My find-
ings support the speculative autoregulatory mechanism of the first bromodomain of 
Brd4 but more detailed investigations are necessary to shed light on the autoregulation 
of BET bromodomains.  
 
Figure 2-5 | Characterization of Brd4 f-BD1 mutant. (A) Schematic structure of recombinant 
full-length human Brd4 protein (Brd4-HA) and Brd4 fragments f-BD1 comprising 54-168 aa of 
full-length Brd4. BD1/2 = bromodomain 1/2, ET = extra-terminal domain, PID = P-TEFb-
interacting domain, HA = hemagglutinin tag, NLS = nuclear localization signal. (B) Proliferation 
kinetics. Cells numbers were counted at least every second day over a period of 5 days in total 
for three replicates (rep 1-3). (C) The proportion of GFP-positive, induced cells was determined 
using flow cytometry. 
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For instance, mutations within the N-terminus of Brd4 could reveal those residues that 
facilitate autoinhibition of BD1. In summary, Brd4 fragments that comprise functional 
domains are potent dominant-negative inhibitors. Mutants f3 (inhibition of bromo-
domain function) and f9 (inhibition of P-TEFb-interacting domain function) were con-
sidered as most interesting dominant-negative mutants for inhibition of Brd4 function 
(dnBrd4). In the following experiments the impact of these two mutants on the cellular 
transcriptome of Raji cells was compared with the impact of JQ1. 
2.3 Raji and H1299 cells have differential sensitivity to JQ1 
Human cancer cell lines differ in their response to JQ1 (Mertz et al. 2011). To assess the 
individual sensitivity of Raji and H1299 cells, I performed proliferation assays in the 
presence of JQ1. Cells were treated with increasing concentrations of JQ1 for 72 h and 
cell proliferation was determined using an MTS-based colorimetric readout. Prolifera-
tion of H1299 cells was reduced to 50% (GI50) at a JQ1 concentration of ~ 2 µM, whereas 
the GI50 for Raji cells was determined as ~ 100 nM (Figure 2-6A). Repression of c-Myc is 
a well-described downstream effect of JQ1 and a major reason for the growth inhibitory 
effects of JQ1 in cancer cell lines (Mertz et al. 2011). Furthermore, the c-Myc gene is 
translocated into the immunoglobulin locus in Raji cells, leading to overexpression of 
this oncogene (Nishikura et al. 1985). Therefore, I determined c-Myc protein levels after 
treatment with 1 µM and 2.5 µM JQ1 for 4 h. In H1299 cells, JQ1 had no effect on c-Myc 
protein levels as determined by Western analysis (Figure 2-6B), although high concen-
trations of JQ1 were used. Conversely, c-Myc signals were markedly decreased in Raji 
cells. These cell line-specific effects suggest that JQ1 acts on biological processes that 
vary among different cell lines. Next, I tested the long-term effects of JQ1 on Raji-luc 
cells, which served as control cell line in the subsequent experiments. I detected com-
plete inhibition of cell proliferation with 500 nM JQ1 (Figure 2-6C). Thus, I considered 
500 nM JQ1 as suitable concentration for the following transcriptome analysis. 
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Figure 2-6 | Sensitivity of H1299 and Raji cells to JQ1 treatment. (A) Cell proliferation at 
increasing JQ1 concentrations (log scale) was determined using a colorimetric assay based on 
MTS metabolization. Measurements were performed for two biological replicates. (B) Cells 
were treated with 1 µM and 2.5 µM JQ1 for 4 h (DMSO as control). Protein levels of c-Myc 
were determined by Western analysis (3E10 anti-myc antibody, anti-α-Tubulin as loading con-
trol). (C) Induced Raji-luc cells were treated with 500 nM JQ1 (red) / DMSO (gray, control) for 8 
days. Living cell numbers were counted and plotted against time. 
 
2.4 Transcriptome analysis of dnBrd4 mutants and JQ1 
2.4.1 Preparation and quality control of RNA-seq libraries 
To characterize genes that are regulated by dnBrd4 mutants and to define the overlap 
between JQ1-regulated genes and dnBrd4-regulated genes, I performed RNA-
sequencing (RNA-seq). In cooperation with Stefan Krebs (group of Helmut Blum, Gene 
Center), libraries of poly(A) enriched RNAs were prepared for five biological replicates 
of f3 and f9 dominant-negative Brd4 mutants, JQ1-treated Raji-luc cells, and DMSO-
treated Raji-luc cells as control. All libraries were prepared 24 hours after inducing the 
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dnBrd4 mutants or 24 hours after adding JQ1. In parallel, sufficient induction was con-
firmed by flow cytometry analysis of eGFP expression (Figure 2-7).  
 
 
Figure 2-7 | Induction of Brd4 mutants used for RNA-seq. Ratios of induced cells (green) vs. 
non-induced cells (grey) were assessed by measuring eGFP reporter signals using flow cytome-
try. Cells were induced by addition of 25 µg/mL doxycycline (dox). 
 
RNA-seq data was analyzed by Michael Kluge (group of Caroline Friedel, LMU). As 
quality control for low variation among the five biological replicates, principal compo-
nent analysis (PCA) was performed. Four clearly separated groups of samples were 
identified by the PCA (Figure 2-8A), corresponding to the four investigated conditions. 
Here, replicates of the same sample clustered closely together and were simultaneously 
separated from other conditions. Furthermore, replicates of f3 and f9 clustered in close 
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proximity, suggesting higher similarities of their transcriptomes compared to the repli-
cates of JQ1, which were more distant to all other conditions in the analysis. 
Higher variation was observed for replicates 2 and 5 of condition f3 (f3-2 and f3-5), 
which did not cluster as closely with the rest of the f3 replicates. Similar results were ob-
tained when performing hierarchical clustering analysis based on the Euclidean distance 
(Figure 2-8B). Here, f3-5 clustered with the remaining f3 replicates, while f3-2 clustered 
close to the DMSO-treated Raji-luc control group. Thus, replicate f3-2 was excluded 
from further analysis. In summary, this demonstrated high quality of the RNA-seq da-
tasets, allowing for an in-depth differential expression analysis. 
 
 
Figure 2-8 | Clustering analysis of RNA-seq samples. (A) Principal component analysis (PCA) 
of 20 RNA-seq samples; 5 replicates per condition. f3 replicate no. 2 (f3-2) did not cluster 
properly with the other f3. (B) Hierarchical clustering analysis based on the Euclidean distances 
between the normalized read counts. Replicate f3-2 (marked in red) clustered with the control 
group and was thus excluded from further analysis. 
 
2.4.2 JQ1 and dnBrd4 mutant f3 regulate a common set of genes 
Next I asked how JQ1 treatment and expression of dnBrd4 in mutant f3 affect the tran-
scriptome. To this end, differential expression analysis relative to the DMSO-treated 
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Raji-luc control was performed and the overlap of differentially expressed (DE) genes 
(p-value ≤ 0.05, no fold-change cutoff) was calculated. Remarkably, 66% and 55% of 
expressed genes were significantly differentially expressed under JQ1 treatment and ex-
pression of the f3 mutant, respectively, indicating substantial deregulation of gene ex-
pression. More importantly, 4971 of 7745 JQ1-regulated genes (64%) were also 
regulated by f3 (Figure 2-9A, left).  
 
 
Figure 2-9 | Differential expression analysis. Differential expression analysis was performed 
using three different programs: limma, edgeR and DEseq2. Genes that were found significantly 
(p-value ≤0.05) differentially expressed with at least 2 out of the 3 programms (DE genes) were 
used for further analysis. (A) Significantly (p-value: ≤0.05) differentially expressed genes of f3, f9 
and JQ1-treated Raji cells were plotted as Venn diagram to visualize commonly regulated 
genes (left). DE genes were further filtered by applying increasing fold-change filters (≥ 1.5-
fold, center; ≥ 2-fold, right). The percentage of JQ1-unique genes (green) relative to the total 
number of DE genes that passed the filter was calculated. (B) DE genes were split into com-
monly repressed (left), commonly induced (center) and inconsistent genes (right). A gene was 
considered as inconsistently regulated when it was upregulated in one group and downregu-
lated in another group. 
 
Results  31 
 
This suggests that Brd4 fragment f3 comprising BD2 potentially inhibits Brd4 similar to 
JQ1 by blocking the bromodomain function. Notably, the direction of the change in 
gene expression was the same for DE genes of JQ1 and f3 conditions: 95 % of the com-
mon DE genes were consistently repressed (2395) or induced (2321) by both f3 and JQ1 
(Figure 2-9B) and the rank correlation between corresponding fold-changes was 0.84. 
Thus, JQ1 and dnBrd4 f3 regulate the transcriptome of Raji cells in a very similar man-
ner with the same set of genes being either repressed or induced. 
2.4.3 Brd4 PID is linked to bromodomain function 
Since both, JQ1 and f3, inhibit the bromodomain function of Brd4, I further investigat-
ed the consequences of inhibiting the P-TEFb interacting PID domain of Brd4. For this 
purpose I compared the transcriptomes of dnBrd4 mutants f9 and f3. Strikingly, f9 DE 
genes accounted for 4808 of f3 DE genes (75%) (Figure 2-9A, left) and rank correlation 
of significant fold-changes was 0.93. This demonstrates that dnBrd4 mutants f3 and f9 
regulate a large set of common genes in a similar way, and further suggests that the gene 
regulatory activity of Brd4 requires the PID domain. Next I compared the transcrip-
tomes of f9 and JQ1-treated cells. Here, f9 DE genes accounted for 5013 DE genes of 
JQ1-treated cells (65%) with a rank correlation of fold-changes of 0.9. This implies that 
disruption of the Brd4 PID function has similar effects on the transcriptome as JQ1. In 
summary, inhibition of BD2 and PID domains of Brd4 caused strongly overlapping 
changes in gene expression, suggesting that both domains are functionally linked. 
2.4.4 JQ1 deregulates gene expression more strongly than dnBrd4 
mutants 
Interestingly, comparison of median fold-changes of regulated genes between the differ-
ent conditions indicated that the effect of JQ1 on gene expression was more pronounced 
than for the dnBrd4 mutants. While median fold-changes for either up- or down-
regulated genes were ~ 1.46 for the dnBrd4 mutants, under JQ1 treatment they were 
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~ 1.52 for up-regulated genes and 1.67 for down-regulated genes. Although these differ-
ences are small, they are highly statistically significant (Wilcoxon rank sum test, p-value 
<10-5) and have a considerable effect on the number of DE genes identified at different 
fold-change cut-offs. When I successively applied ≥ 1.5-fold and ≥ 2-fold-change filters 
to the dataset of DE genes, the resulting Venn diagrams revealed that more JQ1-
regulated genes (1949 at fold-change 2) passed these increasing filters compared to 
genes regulated by mutants f3 and f9 (811 and 759, respectively, Figure 2-9A). This indi-
cates that JQ1 affects gene expression more strongly than dnBrd4 mutants f3 and f9. 
2.4.5 Genes activated by Brd4 inhibition 
Previous studies on transcriptomic changes induced by BET-inhibitors mainly focused 
on downregulated genes and thereby highlighted the activating function of Brd4. To 
investigate also the repressive role of Brd4, I compared up- and downregulated genes. 
Surprisingly, in all three groups around 50% of genes were upregulated (Figure 2-10), 
suggesting that Brd4 is not only activating transcription but is also involved in the re-
pression of many genes. This repression of many genes is not necessarily due to direct 
transcriptional repression by Brd4, but possibly a downstream effect resulting from 
Brd4-mediated upregulation of transcriptional repressors. For instance, cyclin depend-
ent kinase inhibitors CDKN1B and CDKN2B, which are significantly upregulated by f3, 
f9 and JQ1 (1.59-fold to 3.7-fold) (Table 2-1A), have been shown to be transcriptionally 
repressed by c-Myc (Herkert & Eilers 2010). 
 
Figure 2-10 | Distribution of median log2 fold-
change for DE genes. Induced genes were plotted 
above the dashed line, reduced genes below. Median 
log2 FCs were calculated using the log 2 FC values 
determined by the differential expression programs 
that found a statistical significant change (p-value: 
≤0.05; at least 2 out of limma, edgeR, DEseq2). 
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Another interesting set of genes upregulated by f3, f9, and JQ1 are AFF1, AFF4, and 
AF9, members of the super-elongation complex (SEC) (Table 2-1B). Since SEC, like 
Brd4, binds P-TEFb (Lin et al. 2010; Lu et al. 2016), this suggests a balancing mechanism 
in which SEC is upregulated upon inhibition of Brd4. So far, little is known about tran-
scriptional regulation of the corresponding genes, making it difficult to propose a de-
tailed mechanism. Nevertheless, these regulatory circuits further exemplify the complex 
role of Brd4 in transcriptional gene regulation. 
 
Table 2-1 | Differential expression analysis of representative genes. Representative genes 
were listed according to the median log2 fold changes (FC) determined for the JQ1 samples. 
Median log2 FCs were calculated using the log 2 FC values determined by the differential ex-
pression programs that found a statistical significant change (p-value: ≤0.05; at least 2 out of 
limma, edgeR, DEseq2). Upregulated genes are labeled in blue, downregulated genes are 
labeled in green. NS (not significant). (A) c-Myc and c-Myc-regulated genes. (B) Genes encod-
ing for subunits of the super elongation complex (SEC). 
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2.4.6 Brd4 DE genes are enriched for c-Myc target genes 
C-Myc and c-Myc-regulated genes are well known downstream targets of JQ1 and are 
described as main mediators of the anti-proliferative effects of BET inhibition (Delmore 
et al. 2011; Mertz et al. 2011). I tested if c-Myc target genes are enriched in f3 and f9 DE 
genes in a comparable manner as JQ DE genes. To this end gene set enrichment analysis 
(GSEA) was performed using ranked lists of JQ1, f3, and f9 DE genes.  
 
 
Figure 2-11 | Gene set enrichment analysis (GSEA) of c-Myc target genes. (A) c-Myc signa-
ture enrichment plots in Raji-luc + 500 nM JQ1, Brd4 f3, and Brd4 f9 cells versus DMSO-
treated Raji-luc cells as a control for all three conditions. Plots were prepared using the 
SCHUHMACHER_MYC_TARGETS_UP dataset (Schuhmacher et al. 2001) available at the Mo-
lecular Signatures Database (Liberzon et al. 2011). c-Myc target genes were enriched at the 
bottom of the ranked list of genes obtained from the previous DE analysis. (B) Table of select-
ed c-Myc target gene sets enriched in all three samples (Acosta et al. 2008; Bild et al. 2006; 
Kim et al. 2006; O’Donnell et al. 2006; Schlosser et al. 2005; Yu et al. 2005; Zeller et al. 2003). 
n = number of genes in each set; NES = normalized enrichment score; FDR q-val = test of sta-
tistical significance. 
 
I detected significant (FDR q-val < 0.001) enrichment of c-Myc target genes at the 
bottom of the ranked list, demonstrating that c-Myc-regulated genes are similarly 
downregulated in all three conditions (Figure 2-11A). Importantly, the enrichment for 
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c-Myc target genes was robustly reproduced for numerous other available gene sets 
(Figure 2-11B) (Acosta et al. 2008; Bild et al. 2006; Kim et al. 2006; O’Donnell et al. 
2006; Schlosser et al. 2005; Schuhmacher et al. 2001; Yu et al. 2005; Zeller et al. 2003). In 
summary, the proliferation defects observed in f3 and f9 mutant cell lines are likely to be 
mediated by targeting c-Myc and c-Myc-regulated expression patterns. This further il-
lustrates that the mechanisms of dominant-negative inhibition of Brd4 and BET inhibi-
tion using JQ1 largely overlap. 
2.5 Establishment and validation of an analog-sensitive Cdk9 
Raji cell line 
Flavopiridol or i-Cdk9 are chemical inhibitors with high specificity for Cdk9. Frequently 
such inhibitors are used to study the cellular functions of Cdk9, assuming that unspecif-
ic effects on functionally related kinases like Cdk7 or Cdk12 are negligible. With the ad-
vent of the CRISPR/Cas9 gene editing technology, genetically manipulated kinases have 
been engineered in a way that allows highly specific inhibition of an individual kinase. 
This so-called ‘analog-sensitive’ (as) kinase technology is based on the mutation of a 
certain amino acid within the ATP-binding pocket of the kinase domain known as 
‘gatekeeper’ (Lopez et al. 2014). Typically, the gatekeeper position is occupied by large 
amino acids like Phenylalanine. In analog-sensitive kinases the gatekeeper is mutated to 
a smaller amino acid. ATP-analogs with a bulky side chain can then be used to specifi-
cally target the analog-sensitive kinase, because their ATP-binding pocket is enlarged 
and can thus accommodate the analog while the wild type kinase cannot, as exemplified 
by a three-dimensional model for Cdk9 (Figure 2-12A-B). 
Analog-sensitive Cdk9 Raji cell lines were engineered by Weihua Qin (Leonhardt 
Group, LMU Biocenter). In total two clones were identified that carried the designed 
Phenylalanine 103 to Alanine (F103A) mutation. 
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Figure 2-12 | Structure of engineered analog-sensitive Cdk9. (A) Schematic targeting strate-
gy of the enlarged ATP-binding site of Cdk9as with the inhibitor 1-NA-PP1. Only when the 
gatekeeper residue F103 is mutated to alanine, the inhibitor can be accommodated. (B) Mod-
eled 3D structure of the ATP-binding pocket occupied by 1-NA-PP1 of wild type Cdk9 (left, 
PDB: 3BLQ, Baumli et al. 2008) in comparison with Cdk9as (right). 3D modeling was performed 
using the USCF Chimera Software (Pettersen et al. 2004).The 3D model illustrates that F103 
sterically interferes with 1-NA-PP1 whereas A103 allows the accommodation of the inhibitor. 
 
One cell clone was homozygous for F103A (Cdk9as), the second clone was heterozy-
gous for the gatekeeper mutation but additionally gathered a deletion within the second 
allele resulting in a premature STOP codon after the first N-terminal 100 amino acids 
(Cdk9STOP/as). Because it can be assumed that the Cdk9STOP allele is non-functional, both 
cell lines were considered to solely express analog-sensitive Cdk9. 
2.5.1 Inhibition of analog-sensitive Cdk9 decreases cell proliferation 
To further characterize the Cdk9as cell lines, I determined their sensitivity to the inhibi-
tory Adenine analog 1-NA-PP1 in a proliferation assay. Cells were treated with increas-
ing concentrations of 1-NA-PP1 for 72 h and cell proliferation was detected using an 
MTS-based colorimetric readout. Cell growth of both analog-sensitive cell lines was in-
hibited by ≥ 50% at 1-NA-PP1 concentrations of 5 µM or higher (Figure 2-13A). Wild 
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type Raji cells were only slightly affected at very high concentrations. Given these re-
sults, 5 µM and 10 µM were considered as ideal concentrations of the inhibitor for the 
following experiments.  
 
 
Figure 2-13 | Proliferation kinetics of Cdk9as cell lines. (A) Cell proliferation at increasing 
concentrations of 1-NA-PP1 (log scale; relative to DMSO control) was determined using an 
MTS-based colorimetric assay. Measurements were performed for two biological replicates 
after 72 h of treatment. (B) Long-term cell proliferation was assessed in presence or absence of 
5 µM 1-NA-PP1 (DMSO as control) over a time course of 5 days. 
 
Next, I performed long-term proliferation kinetics to assess the overall growth be-
havior of CDK9as and CDK9STOP/as cells in comparison to wild type cells. The prolifera-
tion rates were measured by monitoring the living cell number for 5 days. Untreated 
Cdk9as cell lines proliferated 2-3 times slower compared to the wild type (Figure 2-13B). 
Inhibition of Cdk9as with 5 µM 1-NA-PP1 substantially reduced proliferation of the 
mutated cell lines further, while wild type cells only responded weakly. This first charac-
terization of analog-sensitive Cdk9 cell lines revealed that inhibition of Cdk9as with 
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1-NA-PP1 in the low micromolar range decreases cell proliferation and that this effect is 
specific for the cells with an F103A mutation in the Cdk9 gene. 
 
2.5.2 Inhibition of analog-sensitive Cdk9 reduces phosphorylation of 
Pol II CTD 
Cdk9 phosphorylates the C-terminal domain (CTD) of RNA polymerase II (Pol II). Ac-
cordingly, inhibition of Cdk9 with Flavopiridol reduces CTD Ser2-P as determined by 
Western analysis and mass spectrometry (Schüller et al. 2016). However, it remains un-
clear whether inhibition of other CTD kinases including Cdk12 contributes to the loss 
of CTD phosphorylation. Analog-sensitive Cdk9 cell lines provide an approach to inves-
tigate the effects on CTD phosphorylation in a Cdk9-specific manner. I treated cells 
with 10 µM 1-NA-PP1 for 15 min, 2 h, and 8 h and assessed the effect on CTD phos-
phorylation using specific antibodies against the Pol II large subunit Rpb1 and phospho-
specific CTD antibodies. After 15 min signals for the hyper-phosphorylated IIo form of 
Rpb1 were reduced while the hypo-phosphorylated IIa form was increased in both 
CDK9as and CDK9STOP/as whereas no effect was detected for wild type cells (Figure 2-14, 
compare lanes 7 & 12 to lane 2). This suggests that the amount of phosphorylated Pol II 
CTD is dramatically reduced upon specific inhibition of Cdk9. Indeed, the IIo form of 
both phosphorylated Ser2 and Ser5 were reduced as well, which was more pronounced 
in CDK9STOP/as cells. Reduction of CTD phosphorylation was even more substantial after 
2 h of treatment, whereas after 8 h a recovery of phosphorylation signals was observed. 
In CDK9wt cells 1-NA-PP1 had no detectable effect on CTD phosphorylation at any time 
point. Interestingly, for Ser5-P signals an intermediate band became visible just below 
the reduced IIo form after 15’ and 2 h. Levels of Cdk9 and α-Tubulin were determined 
as loading controls. This analysis after specific inhibition of Cdk9 demonstrates that 
functional Cdk9 contributes to phosphorylation of Pol II CTD. Inhibition of Cdk9 shift-
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ed the IIo to the IIa form, which was paralleled by reduced Ser2-P signals and an altered 
band pattern of Ser5-phosphorylated Pol II in western blot. 
 
 
Figure 2-14 | Inhibition of Cdk9as with 1-NA-PP1 reduces CTD phosphorylation signals. 
CDK9wt, CDK9as, and CDK9STOP/as cells were treated with 10 µM 1-NA-PP1 for 15 min, 2 h, and 
8 h. Untreated and DMSO-treated cells were used as controls. Phosphorylation levels of Pol II 
CTD were assessed by means of Western analysis using antibodies against Pol II large subunit 
Rpb1, CTD phosphorylated at Ser2 and Ser5. Cdk9 and α-Tubulin served as loading control. 
 
2.5.3 Inhibition of Cdk9as is rescued via ectopic expression of 
wildtype Cdk9 
Next I treated Cdk9as with lower concentrations of the inhibitor to determine how pro-
nounced the effect of Cdk9 inhibition on CTD phosphorylation is. While the effects af-
ter 15 min were barely detectable, Pol II phosphorylation signals were markedly reduced 
after 2 h when using 2.5 µM or 5 µM 1-NA-PP1 (Figure 2-15A). This highlights that the 
PP1 analog potently inhibits the CTD kinase activity of Cdk9as. Subsequently, I per-
formed a Cdk9 rescue assay to demonstrate that the reduction of CTD phosphorylation 
is due to a loss of Cdk9 activity. To this end, Cdk9as cells were transfected with a plasmid 
that allows inducible expression of wild type Cdk9-HA.  
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Figure 2-15 | Decreased CTD phosphorylation in Cdk9as cells is rescued by ectopic ex-
pression of wild type Cdk9. (A) CDK9as cells were treated with 2.5 µM and 5 µM 1-NA-PP1 for 
15 min and 2 h each. CTD phosphorylation signals were subsequently detected in Western 
analysis. (B) CDK9as cells were transfected with an inducible wild type Cdk9-HA expression 
plasmid. Cells were treated with 1-NA-PP1 (DMSO as negative control) and the effect of ectop-
ic wild-type Cdk9 expression on CTD phosphorylation was determined by means of Western 
analysis. 
CTD phosphorylation signals were reduced upon 1-NA-PP1 treatment as observed in 
the previous experiments (Figure 2-15B, compare lanes 1 and 3). Induced expression of 
wt Cdk9-HA in untreated cells caused a moderate increase of Rpb1 IIo form and Ser2-P 
(lane 2), highlighting the potential role of Cdk9 as a Ser2 kinase. Notably, in presence of 
1-NA-PP1, no reduction of CTD phosphorylation was detected after ectopic expression 
of wt Cdk9-HA (lane 4). This suggests that Cdk9 is specifically targeted by 1-NA-PP1 
and induced expression of functional wild type Cdk9 rescues this phenotype. 
2.6 Analysis of the transient transcriptome of Cdk9as cells 
The outstanding role of Cdk9 to release paused polymerases from the elongation block 
has been investigated extensively. Still, the impact of Cdk9 function on the production 
of nascent RNA transcripts remains unclear, mainly due to the lack of specific Cdk9 in-
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hibitors as well as proper sequencing technology. Specific inhibition of Cdk9 in analog-
sensitive Raji cells in combination with the recently developed transient transcriptome 
sequencing (TT-seq) (Schwalb et al. 2016) provide a solution to these limitations. 
2.6.1 Preparation and quality control of transient transcriptome se-
quencing (TT-seq) libraries 
In collaboration with Saskia Gressel (group of Patrick Cramer, MPI Biophysical Chem-
istry, Göttingen), I prepared TT-seq libraries from Raji Cdk9as cells. Bioinformatics 
analysis was performed by Björn Schwalb (group of Patrick Cramer). Duplicates of cells 
were treated with 5 µM 1-NA-PP1 (DMSO as control) for 10 min (Figure 2-16A). This 
was followed by 5 min of incubation with 4-thiouridine (4sU), an uridine analog that 
allows labeling of newly synthesized RNAs (Dölken et al. 2008).  
 
Figure 2-16 | Experimental setup and quality control of TT-seq. (A) Raji CDK9as cells were 
treated with 5 µM 1-NA-PP1 or DMSO for 10 min (1.). To label nascent RNAs, 4sU was added 
for 5 min (2.) and total RNA was extracted (3.). Extracted RNA was fragmented (4.) and affinity 
purification was performed (5.) to select for 4sU-labelled RNA (6.). This was followed by library 
preparation (7.). (B) TT-seq fragment size distributions were similar among all samples and the 
average fragment size was ~170 nt. (C) Scatter plots with color encoded density estimation 
comparing TT-seq readcounts of two replicates with DMSO (left) and 1-NA-PP1 (right) treat-
ment (Spearman correlation coefficient 1 for both). 
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After extraction of the total RNA, the transcripts were fragmented to a size of ~ 170 nt 
(Figure 2-16B). This fragmentation step is crucial to remove the unlabeled 5’ regions of 
the transcripts that were transcribed prior to labeling. 4sU-labeled RNA was subjected 
to thiol-specific biotinylation, affinity-purified and used to prepare cDNA libraries for 
transcriptome sequencing. TT-seq readcounts were highly reproducible amongst the 
two replicates for each condition, DMSO and 1-NA-PP1, as demonstrated by a Spear-
man correlation coefficient of 1 for both (Figure 2-16C). The high quality of the TT-seq 
data allowed for complete mapping of transcription units (TU) before and after inhibi-
tion of Cdk9. TUs were defined for each annotated gene as the combination of all tran-
script isoforms (UCSC RefSeq GRCh38). 
 
2.6.2 Cdk9 inhibition decreases RNA synthesis in the 5’-region of 
genes 
Cdk9 regulates pause release and is therefore expected to be critical for processive elon-
gation of many genes. To characterize the role of Cdk9 for efficient RNA synthesis, the 
differential TT-seq reads were compared before and after 10 min inhibition of Cdk9 
(Figure 2-17A). Reduced RNA synthesis was observed at the 5’-region of genes, as ex-
emplified by the HEATR3 gene (Figure 2-17B). From ~20 kilobases (kb) on, nascent 
RNA levels were the same for both DMSO- and 1-NA-PP1-treated cells. This indicates 
that polymerases, that had already been engaged in productive elongation before inhibi-
tion of Cdk9, were unaffected and continued transcribing. In contrast, polymerases that 
had been paused at the promoter proximal region were blocked. This resulted in a so-
called ‘response window’ that corresponds to the time of Cdk9 inhibition and was 
mapped to the 5’end of genes. Notably, the response is characterized by a marked de-
crease of nascent RNA production. 
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Figure 2-17 | Cdk9 inhibition decreases RNA synthesis in the 5’-region of genes. (A) Model 
of the inhibition of Cdk9as with 1-NA-PP1 (5 µM, 10 min) and subsequent 4sU labeling of nas-
cent RNAs for 5 min. (B) Relative TT-seq signal (coverage) with 1-NA-PP1 or DMSO treatment 
at the HEATR3 gene (1-NA-PP1 in red / DMSO in black). The grey box depicts the transcript 
body from transcription start site (TSS, black arrow) to polyA site (pA). The response window is 
set from 200 bp downstream of the TSS and spans the region with decreased TT-seq signals 
after Cdk9 inhibition. (C) Comparison of the average TT-seq signal of expressed TUs (RPK of 20 
or higher) aligned at the TSS with 1-NA-PP1 or DMSO treatment for 954 out of 2,539 investi-
gated TUs ≥ 50 kb. Shaded areas around the average signal (solid lines) give confidential inter-
vals of the average signal. (D) Response to 1-NA-PP1 treatment for 2,539 investigated TUs 
defined as 1 - (1-NA-PP1/DMSO) ×100 for a window from the TSS to 10 kb downstream ex-
cluding the first 200 bp depicted as a violin plot. The median response (55 %) is illustrated with 
a red line. 
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Since pausing does not occur at all genes at a similar level, next the response to Cdk9 
inhibition was investigated genome-wide. To this end metagene analysis was performed, 
comparing the average TT-seq signal of expressed TUs (reads per kilobase [RPK] of 20 
or higher) with 1-NA-PP1 or DMSO treatment. 954 out of 2,539 investigated TUs were 
aligned at the TSS (> 50 kb in length) for two merged replicates. The metagene analysis 
revealed that the 1-NA-PP1-induced reduction of RNA synthesis at the 5’-region of 
genes can also be observed genome-wide (Figure 2-17C). Moreover, the average width 
of the response window was 23 kb. To describe the response of genes to Cdk9 inhibition 
in a more quantitative way, response ratios were calculated for applicable TUs. Applica-
ble TUs synthesized RNA, harbored a single TSS, and exceeded 10 kb in length (2,539 
TUs). The response ratio of TUs varied between 0% to 100% (fully responding TUs) 
with a median of ~ 55% (Figure 2-17D). A remaining TT-seq signal in the response 
window reflects the subpopulation of polymerases that proceeds to productive elonga-
tion independent of Cdk9 kinase activity.   
2.6.3 RNA polymerase II pausing delimits transcription initiation 
Cdk9 inhibition decreased productive elongation of transcription within the response 
window but allowed normal transcription beyond this window. Therefore, I asked if 
initiation was affected upon inhibition of Pol II pause release. Based on the TT-seq data 
the elongation velocity was calculated and the mean was determined as 2.7 kb per mi-
nute (Figure 2-18A). TT-seq further enables calculation of the initiation frequency. In 
average 2.7 initiation events per cell per minute were calculated (Figure 2-18B). To cor-
relate the TT-seq data with Pol II pausing, available mammalian NET-seq (mNET-seq) 
data derived from the nuclear chromatin fraction from HeLa cells was used (Nojima et 
al. 2015). In mNET-seq the 3’-end of nascent RNA that is still associated with the poly-
merase is sequenced and thus can be mapped to the genome. This allows determination 
of the precise position of transcribing polymerases. 
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Figure 2-18 | RNA polymerase II pausing affects transcription initiation. (A-C) Histograms 
depicting the distribution of elongation velocity, initiation frequency [cell-1min-1], and pause 
position distance from the TSS. (D) Schematic representation of integrated measures to inves-
tigate the polymerase dynamics in the promoter-proximal region. Upper panel: mNET-seq sig-
nal as a product of initiation frequency (I) and elongation velocity (v) of the polymerase. Middle 
panel: Polymerase movement with 4sU labeled RNA fragments according to TT-seq with a 
RNA labeling time of 5 min. Fragment length is determined by elongation velocity of the re-
spective polymerase. Lower panel: TT-seq signal strength equals initiation frequency. (E) Histo-
gram depicting the distribution of pause duration. (F-G) Distributions of gene-wise pause 
duration and initiation frequency for TUs with a response ratio > 75% quantile (603 TUs) and 
TUs with a response ratio < 25% quantile (527 TUs). (H) Comparison of the initiation frequency 
to the pause duration for 2,284 common TUs with color encoded density estimation (Spearman 
correlation coefficient -0.54). Grey shaded area depicts impossible combinations of the two 
measures given the Ehrensberger inequality and a polymerase footprint of 50 bp 
(Ehrensberger et al. 2013). 
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90% of the TUs derived from the TT-seq approach showed Pol II pausing signals above 
background. Alignment of the pause sites relative to the TSS revealed that the pause po-
sition varies for the different TUs, with most pause sites located ~80 bp downstream of 
the TSS (Figure 2-18C).  
 Neither TT-seq nor mNET-seq data alone can provide information about the dy-
namics of Pol II pausing. To quantify the pause duration, both approaches were com-
bined. The mNET-seq signal provides the number of polymerases within the pause 
window, which is determined by the initiation frequency I and the pause duration d 
(Figure 2-18D). As demonstrated, I could be obtained from TT-seq. Furthermore, d is 
proportional to the ratio of the mNET-seq signal over I, enabling the calculation of the 
pause duration d, which was on average 1.9 minutes (Figure 2-18E). Pause durations 
were significantly longer (Wilcoxon rank sum test, p-value < 10-16) and initiation fre-
quencies were lower for TUs that showed a strong reduction of RNA synthesis (Figure 
2-18F-G). This led to the question whether pause duration is generally related to tran-
scription initiation. Pause duration was plotted against initiation frequency of 2,284 
common TUs and a robust anti-correlation between the two factors was observed 
(Spearman correlation coefficient -0.54) (Figure 2-18H), demonstrating that genes with 
shorter pausing exhibit higher initiation frequencies and more RNA synthesis. Togeth-
er, combined analysis of independent mNET-seq and TT-seq data indicates that pause 
duration and initiation frequency for each gene are globally related. 
To test directly if longer pause durations lead to lower initiation frequencies, TT-seq 
data after Cdk9 inhibition was further analyzed. Cdk9 inhibition resulted in significantly 
less labeled RNA between the TSS and the pause site (Wilcoxon rank sum test, p-value < 
10-15) (Figure 2-19A and C). Strikingly, initiation frequencies were significantly reduced 
as well after Cdk9 inhibition (Wilcoxon rank sum test, p-value < 10-16) (Figure 2-19B-
C). Because Cdk9 specifically targets paused Pol II, these results strongly suggest that 
pausing controls initiation. 
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Figure 2-19 | Increasing pause duration suppresses transcription initiation. (A) Distribution 
of gene-wise mean TT-seq signal in the region between TSS and the pause site for DMSO 
(control) or 1-NA-PP1 treatment normalized to initiation frequency before treatment. (B) Com-
parison of gene-wise initiation frequencies after DMSO or 1-NA-PP1 treatment. (C) Schematic 
representation of the reduced labeled RNA levels within TSS and pause site as a consequence 
of downregulated initiation frequency. 
 
2.6.4  Sensitivity to Cdk9 inhibition correlates with Brd4 occupancy 
Paused Pol II is typically associated with negative elongation factors DSIF and NELF 
whereas Brd4 and Cdk9 regulate the release into productive elongation. To investigate 
which factors preferentially occupy pause windows with longer pause durations, ChIP-
derived factor occupancies were correlated with the pause durations defined above. Im-
portantly, this is possible because available ChIP-seq signals could be normalized with 
the inititation frequency, i.e. the number of polymerases released from the pause win-
dow per time (pause release rate). This normalization is crucial, because ChIP-derived 
factor occupancies are artificially high in pause windows with long pause durations 
(Ehrensberger et al. 2013). Correlation of normalized ChIP signals in the pause window 
with pause durations was positive for the factors NELFe, Cdk9, and Brd4. 
Results  48 
 
Because Brd4 occupancy is high at enhancers (Lovén et al. 2013), long range chromatin 
interactions of strongly and weakly Cdk9-responding TUs were compared. Indeed, 
Cdk9-responding TUs showed a higher tendency to establish such chromatin interac-
tions, as observed by Hi-C (Ma et al. 2015). Together these observations highlight that 
Brd4 and Cdk9 regulate the release of paused polymerases and that this regulation pre-
sumably involves chromatin looping to distant enhancers. 
 
 
Figure 2-20 | Transcription- and chromatin-associated factors correlate with CDK9as re-
sponse. (A) Pairwise spearman correlation (color encoded, -0.20 in blue to 0.21 in red) using 
ChIP measurements of Cdk9, NELFe and Brd4 of the promoter region (TSS – 250 bp to TSS) 
and pause window against the response to Cdk9 inhibition (see Figure 2-17) shown as a 
heatmap. Analysis was performed in three different ways: ChIP-derived occupancies were ei-
ther normalized to pause duration (release), normalized to total Pol II (Pol II), or the raw signal 
was used (raw) (for references of ChIP measurements see Table 4-3). (B) Comparison of the 
average Hi-C signal (detecting long-range chromatin interactions) aligned at the pause site for 
strong responding TUs (response ratio > 75% quantile, 602 TUs) and weakly responding TUs 
(response ratio < 25% quantile, 528 TUs). Confidence intervals are provided as shaded areas 
around the average signal (solid lines). 
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3 Discussion 
3.1 Dominant-negative mutants of Brd4 inhibit cell proliferation 
of tumor cell lines 
Many studies have used small molecule inhibitors such as JQ1 to inhibit Brd4 and study 
its cellular function as well as its role in malignant diseases. However, the use of JQ1 is 
limited as this inhibitor also targets other proteins of the BET family and its mode of 
action is the disruption of bromodomain function alone. Thus, I aimed to inhibit Brd4 
without using JQ1 or a similar inhibitor but to overexpress dominant-negative (dn) 
Brd4 mutants instead. I designed multiple Brd4 fragments that together cover the whole 
sequence of full-length Brd4. Besides the two N-terminal bromodomains other Brd4 
domains support seminal functions as well (Figure 3-1). 
 
 
Figure 3-1 | Brd4 is a histone reader with many interaction partners. In addition to acetyl-
lysine binding bromodomains, Brd4 comprises several other domains that interact with factors 
involved in transcription and chromatin regulation. PDID/BID bind p53 and binding of BD2 to 
acetylated histones is regulated by CK2-dependent phosphorylation of PDID. ET recruits his-
tone demethylase JMJD6 and histone methyltransferase NSD3, which can trimethylate H3K36. 
The putative HAT domain was described to acetylate H3K122 (Devaiah et al. 2016). P-TEFb is 
recruited via dual binding of BD2 to acetylated CyclinT1 and PID to Cdk9. 
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Deletion of the C-terminal PID domain abolishes the interaction with Cdk9 (Bisgrove et 
al. 2007). The extra-terminal domain (ET) is essential for interaction with multiple pro-
teins including NSD3 and JMJD6 (Rahman et al. 2011). Hence it is of great interest to 
additionally disturb the function of those domains using the approach of dn Brd4 mu-
tants. Notably, all important domains of Brd4 could be specifically inhibited by distinct 
mutants, allowing a broader and yet more precise targeting approach compared to the 
use of JQ1. Screening of this set of potential dn Brd4 mutants for aberrant proliferation 
identified several mutants that exhibit a dominant-negative phenotype. Generally, all 
mutants that comprise one of the described Brd4 domains (BD1, BD2, BID/PDID, ET, 
and PID) markedly inhibited cell proliferation of Raji and H1299 cells. 
The expression levels of the different Brd4 fragments varied substantially, raising the 
question whether the dn phenotypes I observed for some fragments are solely due to a 
general overexpression defect. Expression levels of f3, f5, and f6 were very high and in all 
three mutants I observed reduced proliferation in either Raji or H1299 cells or both. In 
contrast, f4 and f9 were expressed at markedly lower levels. However, this was sufficient 
to slow down proliferation in Brd4 mutants f4 and f9 as well. Notably, adequate expres-
sion of the fragments is a prerequisite to achieve dominant-negative inhibition of en-
dogenous Brd4. 
While JQ1 inhibits both bromodomains of Brd4, my dn approach allows targeting of 
BD1 (f1 and f-BD1) and BD2 (f3) separately. I detected reduced proliferation in f-BD1 
and f3 mutant cells but not in the f1 mutant. Similar to f-BD1 and f3, a dual bromo-
domain construct (BD1/BD2) was reported as dn inhibitor before (Wang et al. 2012). 
Specifically, this mutant displaced full-length Brd4 from chromatin and induced a frag-
mented chromatin phenotype in a cervix carcinoma cell line. This suggests a compara-
ble mode of inhibition for f-BD1 and f3, since both potentially disrupt the function of 
Brd4 bromodomains. 
Nevertheless, BD1 and BD2 may fulfill separate roles, as demonstrated by the differ-
ential effects on cell proliferation of f1 and f3. This is supported by several other studies. 
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In the phylogenic tree of bromodomains, BD1 and BD2 domains of BET proteins repre-
sent individual branches (G. Zhang et al. 2015). Furthermore, the binding affinities to 
JQ1 and histone recognition preferences differ between the two domains. In vitro bind-
ing assays for Brd4 indicated best binding of BD1 to H3 and of BD2 to H4 acetylated 
lysine peptides (Vollmuth et al. 2009). In contrast, a more recent study observed that 
BD1 of Brd4 had a high affinity for acetylated H4 in particular while the binding affinity 
of BD2 was less preferential (Filippakopoulos et al. 2012). Both domains displayed effi-
cient binding to JQ1 with dissociation constants (Kd) in the nanomolar range, but BD1 
bound JQ1 stronger than BD2 did (Kd of about 50 nM and 90 nM, respectively) 
(Filippakopoulos et al. 2010). 
Initial pulldown assays with Brd4 deletion mutants suggested that either bromo-
domain can interact with the CyclinT1 subunit of P-TEFb (Jang et al. 2005). Subse-
quently, BD2 of Brd4 was reported to bind acetylated CyclinT1 similarly well as 
acetylated H3 and H4 sequences (Vollmuth et al. 2009). These observations are highly 
interesting, since they describe another function of Brd4 bromodomains besides binding 
of histone tales. Moreover, they imply a second mode of interaction between Brd4 and 
P-TEFb, in addition to PID-Cdk9 binding. Indeed it has been proposed, that binding of 
BD2 to triple-acetylated CyclinT1 primes P-TEFb for full liberation from its inactive 
form upon a second Brd4 binding via the PID domain (Schröder et al. 2012). Together 
these diverse characteristics of BD2 may explain why the f3 mutant severely reduced cell 
proliferation. 
Recently, two novel Brd4 domains were described that are involved in Brd4-p53 in-
teractions (Wu et al. 2013). Phosphorylation-dependent interaction domain (PDID) 
spans amino acids 287-530 and encompasses BD2. Basic residue-enriched interaction 
domain (BID) is located between BD2 and ET, comprising amino acids 524–579. Alt-
hough both domains are conserved in BET proteins, less is known about their function. 
Both domains independently interact with p53 as demonstrated in pulldown experi-
ments (Wu et al. 2013). Further analyses revealed that PDID harbors an N-terminal 
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cluster of phosphorylation sites (NPS) that contains several serine residues that can be 
phosphorylated by casein kinase 2 (CK2). In their final model, Wu and colleagues pos-
tulate that in the non-phosphorylated state NPS binds BD2 and blocks Brd4 binding to 
acetylated chromatin. In this inactive state, p53 can already by recruited to BID. Upon 
CK2-dependent phosphorylation of NPS, the masking of BD2 by NPS is resolved and 
NPS will form an intramolecular contact with BID and simultaneously bind p53. This 
so-called phospho-switch activates Brd4-binding to acetylated chromatin and facilitates 
efficient transcription of p53 target genes including p21 and PUMA. Although mutant 
f3 comprises large parts of PDID it lacks the NPS region. Notably, mutant f4 harbors 
both NPS and BID. Thus the reduced proliferation phenotype in f4 is possibly mediated 
by disruption of the phospho-switch dependent recruitment of p53. 
Mass-spectrometric studies of the Brd4 interactome have identified several proteins 
that interact with the extra-terminal ET domain of Brd4 and these interactions are con-
served in Brd2 and Brd3 (Rahman et al. 2011). The ET-interacting proteins include ar-
genine demethylase JMJD6 and the lysine methyltransferase NSD3. Both proteins are 
recruited to the promoter and gene bodies of Brd4-regulated genes in a Brd4-dependent 
way. Depletion of either NSD3 or Brd4 reduced the levels of H3K36 trimethylation 
(H3K36me3) in the gene body of CCND1 (CyclinD1), a Brd4-regulated gene. 
H3K36me3 is a well-described histone mark of actively transcribed chromatin 
(Kouzarides 2007). Assuming that the dn f5 mutant disrupts NSD3 recruitment via ET, 
this might reduce H3K36me3 levels and repress Brd4-regulated genes. Furthermore, it 
was demonstrated that JMJD6 binds to distant enhancers to control transcriptional 
pause release and that this association is dependent on Brd4 (Liu et al. 2013). Mutant f5 
might abolish Brd4-dependent JMJD6 recruitment to these so-called anti-pause enhanc-
ers, thereby blocking the pause release of enhancer-regulated genes. Taken together, 
these hypothetical events provide possible mechanisms that lead to the anti-proliferative 
phenotype in mutant f5. 
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The Brd4 PID domain is essential for recruitment and activation of P-TEFb 
(Bisgrove et al. 2007). The dominant-negative effect of the f9 mutant which comprises 
the PID was therefore not surprising. Notably, expression of the f9 fragment caused the 
most robust proliferation defects in both Raji and H1299 as compared to all other Brd4 
fragments including f3, which caused a comparably strong reduction of proliferation 
rates. Taking into account that expression levels in f9 were markedly lower than in f3, 
the PID containing f9 fragment can be considered the most potent dn inhibitor of Brd4 
function analyzed in this screen. My findings highlight that the PID domain is crucial 
for regular Brd4 function which will be discussed in more detail in chapter 3.2. 
In summary, the regions of the Brd4 protein whose overexpression lead to a domi-
nant-negative phenotype precisely overlap with already reported domains. Future ef-
forts should focus on the investigation of PDID/BID and ET domains, since our 
understanding about the functions of these certainly important domains is currently 
very limited. The contribution of the C-terminal region of Brd4, connecting ET and 
PID, to the overall function of Brd4 remains elusive. This region of Brd4 might provide 
secondary and tertiary structures that are essential for the correct three-dimensional 
organization of the protein. Furthermore, it was recently reported that Brd4 has histone 
acetyltransferase (HAT) activity that is distinct from other HATs (Devaiah et al. 2016). 
Interestingly, the putative HAT catalytic domain is located within the C-terminal stretch 
(1157-1197 aa in mouse Brd4), providing first insights into the function of this poorly 
understood region of the Brd4 protein. 
3.2 Brd4 is the major mediator of the anti-tumor effects in-
duced by JQ1 and regulates the transcriptome with its 
P-TEFb-interacting domain 
Besides Brd4, JQ1 also targets the other somatic BET members Brd2 and Brd3 
(Filippakopoulos et al. 2010). Thus JQ1 is not BET member specific and any JQ1-
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mediated inhibition of Brd4 might be accompanied by inhibition of Brd2 and Brd3 as 
well. For example is has been demonstrated that knockdown of Brd2 alone or Brd3 
alone inhibits transcription of certain cytokine genes that are also affected by Brd4 
knockdown and inhibited by JQ1 (Belkina et al. 2013). Furthermore, JQ1 affects the 
regulatory function of Brd2, Brd3, and Brd4 on metabolic pathways in the pancreatic β-
cell, as it was demonstrated by using BET-specific siRNAs (Deeney et al. 2016). Brd2 has 
implications on development of cancer as well. Transgenic mice overexpressing Brd2 
restricted to lymphoid cells develop splenic B-cell lymphoma (Greenwald et al. 2004). 
Brd2 interacts with histone variant H2A.Z.2, a recently described mediator of cell prolif-
eration and drug sensitivity in malignant melanoma (Vardabasso et al. 2015). Although 
increasing evidence supports the role of Brd2 and Brd3 as JQ1 targets, many studies still 
consider Brd4 as the major target of JQ1. Especially the anti-cancer effects of JQ1 have 
been mostly attributed to Brd4 due to its c-Myc activating function (Mertz et al. 2011; 
Zuber, Rappaport, et al. 2011). Therefore, dominant-negative Brd4 mutants provide an 
elegant way to specifically target Brd4 and compare the effects on cell proliferation and 
the cellular transcriptome to JQ1.  
 Similar to JQ1, dn Brd4 mutants inhibited cell proliferation of Raji and H1299 cells. 
This suggests that Brd4 function is essential in both cell lines although Raji cells were 
about 20 times more sensitive to the small molecule inhibitor than H1299. Comparison 
of c-Myc protein levels after JQ1 treatment revealed that c-Myc is a major downstream 
target of JQ1 in Raji but not in H1299 cells. Furthermore, the high enrichment of c-Myc 
targets in the Brd4-specific transcriptome datasets support the model that c-Myc down-
regulation by either JQ1 or dnBrd4 inhibitors is largely responsible for the anti-
proliferative effects observed in previous reports and the present study. This suggests 
that the effects of JQ1 treatment are cell line specific and at least in the case of c-Myc 
regulated by Brd4. Cell line specific activity of Brd4 has been reported in the context of 
so-called super enhancers, a highly active class of enhancers that are implicated in defin-
ing cell identity (Lovén et al. 2013) (see chapter 3.6). Hence, the contribution of Brd4 to 
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the anti-proliferative effects of JQ1 should be investigated carefully also on the tran-
scriptome level. 
Comparison of the transcriptome of mutant f3 with the transcriptome of JQ1-treated 
cells revealed major changes in gene expression in both transcriptomes and that the 
dominant-negative mutant f3 repressed and induced almost the same genes as JQ1. I 
further noticed that JQ1 induced higher changes in gene expression in affected genes 
than the f3 mutant. The functions of Brd2, Brd3, and Brd4 partially overlap as demon-
strated for the regulation of cytokine genes using BET member-specific siRNA knock-
downs (Belkina et al. 2013). Thus, higher JQ1-induced changes in gene expression may 
be explained by additional inhibition of Brd2 and Brd3 by JQ1 but not by dominant-
negative Brd4. Alternatively, 500 nM JQ1 might simply be a more potent inhibitor than 
overexpressed Brd4 fragments, both in terms of stability and efficiency. However, the 
groups of regulated genes and the direction of their regulation, induction or repression, 
is largely identical among f3 and JQ1 datasets. Thus, mutant f3 confirms the current 
model that JQ1 may act mainly by inhibiting the interaction of the bromodomains of 
Brd4 and other BET proteins with acetylated histone tails.  
Unlike f3, mutant f9 comprises a domain that is unique for Brd4 and neither present 
in Brd2 nor Brd3: P-TEFb-interacting domain (PID). Pol II undergoes promoter proxi-
mal pausing at 60% of mammalian genes (Day et al. 2016). At those genes, recruitment 
of P-TEFb is essential to release the polymerase from the elongation block. Brd4 recruits 
P-TEFb by binding Cdk9 via the PID domain. In fact, recruitment of P-TEFb might be 
facilitated in two steps. First, acetylated CyclinT1 is bound by BD2 of Brd4 which is fol-
lowed by the described Cdk9-PID interaction, leading to full activation of P-TEFb 
(Schröder et al. 2012). Notably, by using mutants f3 and f9 both steps can be potentially 
targeted.  
I found that changes induced in the transcriptome of mutant f9 largely overlapped 
with the changes that I observed for mutant f3 and JQ1 treated cells. The functional 
overlap of f9 with f3 and JQ1 is further confirmed by the almost identical impact of all 
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three inhibitors on the expression on c-Myc target genes. This result was not necessarily 
expected, because the contribution of the PID domain to the gene regulatory function of 
Brd4 has not been measured quantitatively before. The direct comparison of mutant f3 
and f9 in my study demonstrates that BD2 and PID in Brd4 act as a functional unit and 
that the gene regulation by Brd4 largely depends on PID. However, it remains unclear 
whether the PID does interact only with P-TEFb or in addition with other factors. Here 
I found that a large set of genes activated by JQ1 and mutant f3 is found activated also 
by mutant f9 (for a detailed discussion on activated genes, see chapter 3.3). This may be 
due to downstream effects that are triggered by genes regulated by P-TEFb such as 
c-Myc. Nevertheless, I cannot exclude that the PID domain may have a second, not yet 
identified function that is important for transcriptional repression. Together, my results 
suggest that gene regulatory changes induced by JQ1 can also be induced by dominant-
negative Brd4 mutants, and that the inhibition of the Brd4 PID domain is central for the 
function of BET-inhibitor JQ1. 
The functional link observed between PID and bromodomains of Brd4 raises the 
question how the short isoform of Brd4 (Brd4-s), which lacks the PID (Bisgrove et al. 
2007), is involved in transcriptional regulation and if inhibition of Brd4-s by JQ1 may 
also translate into a phenotype. Brd4-s might act as a dominant-negative inhibitor of 
full-length Brd4, as suggested by previous studies (Alsarraj et al. 2011; French et al. 
2003). However, differential biochemical and nuclear localization properties indicate 
that the two isoforms of Brd4 may fulfill separate roles. Brd4-s localizes specifically to 
the transcriptionally inactive perinuclear region where it might be involved in gene re-
pression (Alsarraj et al. 2013). 
Overexpression of PID in mutant f9 potentially inhibits the recruitment of P-TEFb 
to Brd4 and acetylated chromatin. The inhibitory effect of PID expression or of synthet-
ic peptides containing PID has been reported before. A synthetic peptide comprising the 
PID fused to the protein transduction domain of HIV-Tat abrogated Tat transactivation 
in a luciferase reporter assay (Bisgrove et al. 2007). Overexpression of the PID abrogated 
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binding of full-length Brd4 to P-TEFb but did not lead to defects in chromatin structure 
as observed for overexpression of BD1/BD2 dominant-negative inhibitor (Wang et al. 
2012). Several studies have reported that the PID domain liberates P-TEFb from its in-
active complex containing Hexim1 in vitro (Itzen et al. 2014) and in HEK293T cells 
(Schröder et al. 2012). Both studies strongly suggest that the PID competes with Hexim1 
for binding of P-TEFb. Interestingly, JQ1 affects the cellular equilibrium between active 
and inactive P-TEFb and triggers the transient release of free P-TEFb together with ele-
vated Hexim1 protein levels as a direct compensatory response (Bartholomeeusen et al. 
2012). Activation of P-TEFb upon JQ1 treatment might be a cellular stress response but 
the underlying mechanism is poorly understood. However, transcriptome analyses con-
firm that JQ1 causes elevated Hexim1 expression (Donato et al. 2016; Mertz et al. 2011, 
this study). Upregulation of Hexim1 was observed in mutants f3 and f9 as well, under-
lining that the cellular response to JQ1 primarily depends on targeting Brd4. 
3.3 Brd4 is both a transcriptional activator and repressor 
In the original I-BET report it was carefully noticed that several genes are upregulated as 
a response to inhibition of BET proteins (Nicodeme et al. 2010). Although this activa-
tion may also be a downstream effect, the function of BET proteins as transcriptional 
repressors has been reported repeatedly. Brd2 forms nuclear complexes with Swi/Snf 
chromatin remodelers that co-activate and co-repress transcription (Denis et al. 2006). 
Direct interaction with a chromatin remodeler has been shown for Brd4 which binds 
CHD4 with its ET domain (Rahman et al. 2011). Interestingly, CHD4 is part of the 
mi-2/nucleosome and deacetylase (NuRD) complex which has been implicated in the 
repression of genes that are regulated by estrogen receptor α (Denslow & Wade 2007). 
Furthermore, a recent report demonstrated the repressive role of BET proteins for the 
transcriptional coactivator TAZ (Duan et al. 2016). 
Discussion  58 
 
My results further establish that Brd4 inhibition results in both activation and re-
pression of genes to a similar extent. Interestingly, I observed that AFF1, AFF2 and AF9, 
encoding three major subunits of the super elongation complex (SEC), were upregulated 
by JQ1 as well as in mutants f3 and f9. SEC can also bind P-TEFb (Lin et al. 2010), sug-
gesting a feedback loop and a crosstalk between Brd4 and SEC. In line with this, a recent 
model proposes recruitment of P-TEFb by Brd4 and SEC via different mechanisms (Lu 
et al. 2016). The upregulation of SEC might be a response to Brd4 inhibition to rescue 
RNA polymerase II (Pol II) elongation, in agreement with a recent study that demon-
strated compensatory Pol II loading at JQ1-insensitive genes (Donato et al. 2016). Acti-
vation of transcription might also be a response to the transient release of active P-TEFb 
(see final paragraph of chapter 3.2) which has been observed after JQ1 treatment but 
might also be a response to mutants f3 and f9 (Bartholomeeusen et al. 2012). Upregulat-
ed transcription of SEC subunits further complements the report of Bartholomeeusen 
and colleagues, who detected increased protein levels of P-TEFb-SEC complexes in JQ1-
treated cells. The observation that many genes are upregulated upon inhibition of Brd4 
possibly results from a combination of both downstream effects and revoked transcrip-
tional repression by Brd4. 
3.4 Analog-sensitive kinase technology allows for immediate 
and specific inhibition of Cdk9 
Cyclin-dependent kinase inhibitors like Flavopiridol, i-CDK9 or 5,6-
dichlorobenzimidazole 1-β-D-ribofuranoside (DRB) have high specificities for Cdk9 
(Lu et al. 2015; Wang & Fischer 2008). Amongst all Cdk9 inhibitors, Flavopiridol is the 
compound most often evaluated in clinical trials for cancer therapy (Morales & 
Giordano 2016). However, due to the lack of selectivity against other Cdks and many 
cases of adverse effects in the clinical trials, neither Flavopiridol nor any other Cdk9 in-
hibitor has been allowed for clinical use. Besides clinical aspects, Cdk9 inhibitors are 
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valuable tools to study the role of Cdk9 in transcription regulation. Several studies have 
taken advantage of such inhibitors to assess the function of Cdk9 genome-wide. In glob-
al run-on sequencing (GRO-seq) experiments with Flavopiridol-treated nuclei from 
mouse embryonic stem cells (mESCs), it was shown that pause escape is dependent on 
Cdk9 kinase activity and occurs at all actively transcribed genes (Jonkers et al. 2014). 
Further it was demonstrated that transcription of non-paused genes is reduced as well 
upon inhibition of Cdk9 with DRB in HeLa nuclei (Laitem et al. 2015). Laitem and col-
leagues further describe a poly(A)-associated elongation checkpoint that is essential for 
efficient termination and can be targeted by DRB.  
Unfortunately the described inhibitors target other CTD kinases as well, including 
Cdk7, Cdk12, and Cdk13 (Bensaude 2011; Bösken et al. 2014; Greifenberg et al. 2016). 
Thus, it is not possible to study the kinase activity of one single kinase using such inhibi-
tors. Therefore, I applied the analog-sensitive kinase technology in combination with 
CRISPR/Cas9 gene editing. Analog-sensitive kinases harbor a so-called ‘gatekeeper mu-
tation’ within the ATP-binding pocket. This mutation allows the accommodation of 
bulky Adenine analogs and provides an elegant way to specifically inhibit the analog-
sensitive kinase. First reports on analog-sensitive kinases lead to detailed insights on the 
function of cell cycle kinases including Cdk1 and Cdk2 (Bishop et al. 2000; Kraybill et al. 
2002). However, this strategy has also been applied on the study of CTD kinases. Re-
search on analog-sensitive Cdk7 human colon carcinoma cells revealed that Cdk7 is in-
volved in Cdk1/CyclinB assembly as well as in the activation of Cdk2/cyclin complexes 
(Larochelle et al. 2007). The same cell line was used to study the role of Cdk7 in tran-
scription (Glover-Cutter et al. 2009). Inhibition of Cdk7 suppressed promoter proximal 
pausing and abrogated recruitment of NELF. Furthermore it was demonstrated that 
Cdk7 not only phosphorylates Ser5 of Pol II CTD but additionally phosphorylates Ser7. 
Analog-sensitive kinase technology alternatively allows the use of modified ATP ana-
logs that do not inhibit the kinase but allow the incorporation of labeled phosphates to 
identify protein targets of a specific kinase. In an in vitro phosphorylation assay using a 
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purified Cdk9as in total cell extracts, the substrates of Cdk9 were determined (Sansó et 
al. 2016). This screen identified the ‘torpedo’ exonuclease Xrn2 as a Cdk9 substrate 
providing an explanation for the role of Cdk9 in transcription termination that was dis-
cussed above (Laitem et al. 2015). Interestingly, in the report by Laitem et al. an exoge-
nously expressed Cdk9as was used to confirm that the termination defects are at least 
partly due to Cdk9 inhibition by DRB. 
The studies on analog-sensitive Cdk9 mentioned above relied on complex knock-
down knock-in approaches with ectopic expression of mutated kinases. Therefore, en-
gineering the endogenous Cdk9 gene using CRISPR/Cas9 to derive an analog-sensitive 
cell line, as it was used in the present work, represents a much more elegant way to spe-
cifically target Cdk9. Untreated Cdk9as Raji cells proliferated 2-3 times slower as wild 
type Raji. This phenotype could be explained by reduced kinase activity upon mutation 
of the gatekeeper, which resides within the ATP-binding pocket and potentially causes 
less effective binding or hydrolysis of ATP. Reduced kinase activity is a common obser-
vation in AS kinases and can be overcome by compensatory mutations (Lopez et al. 
2014). An alternative explanation for the reduced proliferation rates of CDK9as cells 
might be its clonal origin, since construction of the cell lines involved single cell cloning. 
Nevertheless, the CDK9as cell line is viable and stably proliferates over weeks. Thus I 
consider the introduced F103A mutation as well tolerated. 
 Results from previous reports suggest that mainly phosphorylation of Ser2 shifts the 
Rpb1 protein band from the hypo-phosphorylated IIa form to the hyper-
phosphorylated IIo form (Chapman et al. 2007; Medlin et al. 2005). Indeed, I found that 
inhibition of Cdk9 resulted in a substantial loss of the slower migrating IIo form. This 
was also observed in Western blots probing for Ser5-P polymerase. Here an intermedi-
ate band appeared that supposedly represents Pol II that has lost Ser2-P but is still phos-
phorylated at Ser5. These results strongly indicate that Cdk9 functions as a Ser2 kinase 
in vivo and that Ser5 kinase activity is limited to in vitro assays. I speculate that Cdk9 
can potentially phosphorylate Ser5 in vivo as well. However, due to extensive Ser5 phos-
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phorylation facilitated by the pre-initiation machinery including Cdk7, most Ser5 resi-
dues are already phosphorylated at this stage and may prohibit further phosphorylation 
by Cdk9. Furthermore association with additional factors including DSIF might influ-
ence the selectivity of Cdk9 in favor of Ser2.  
 The present work represents the second study of CRISPR/Cas9 engineered CTD Ser2 
kinases together with a recent report that described the production of a Cdk12 analog-
sensitive HeLa cell line (Bartkowiak et al. 2015). Similar to inhibition of Cdk9, specific 
targeting of Cdk12 resulted in reduced cell proliferation and disturbed CTD phosphory-
lation patterns, as observed using modification-specific antibodies. The reported and yet 
to be developed analog-sensitive cell lines will be key to unravel the specific functions of 
kinases that are involved in transcription and phosphorylation of the CTD.  
3.5 Pausing controls transcription initiation 
Several next-generation sequencing-based methods have elucidated the dynamics of 
Pol II along the locus of a transcribed gene (Liu et al. 2015). Chromatin immunoprecipi-
tation using Pol II specific antibodies in combination with deep sequencing (ChIP-seq) 
demonstrated that in metazoan cells most genes display high Pol II occupancy 20-60 bp 
downstream of the TSS (Muse et al. 2007; Zeitlinger et al. 2007). This Pol II peak reflects 
polymerases that are paused in the promoter proximal region. The same peak is typical-
ly observed when performing mammalian native elongating transcript sequencing 
(mNET-seq). Here, 3′ ends of nascent transcripts associated with RNA polymerase are 
sequenced and visualized transcription at nucleotide resolution (Nojima et al. 2015). 
GRO-seq-based approaches can directly detect transcriptionally engaged Pol II via in-
corporation of the nucleotide analog bromo-UTP (BrUTP) into the nascent RNA. 
GRO-seq is performed in isolated nuclei and might not reflect the biological situation of 
an intact cell. Nevertheless, it allows assessment of dynamic transcriptional processes by 
deriving pause duration or elongation rates (Jonkers et al. 2014). 
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In this work I performed transient transcriptome sequencing (TT-seq) which is a 
4sU-labeling RNA-seq approach (Schwalb et al. 2016). TT-seq informs on the synthesis 
of nascent RNA and can be combined with mNET-seq data to calculate pause durations. 
The calculated pause durations were in the range of minutes which is generally con-
sistent with previous reports (Jonkers et al. 2014). In contrast, production of a transcript 
from an average protein-coding human gene takes more than 30 minutes. Hence, de-
creasing the pause duration will not increase RNA synthesis per time. To achieve more 
RNA synthesis, higher initiation frequencies are required. Gene activation can increase 
Pol II occupancy in the promoter proximal region (Boehm et al. 2003), highlighting that 
pausing is a rate-limiting step. Together this suggests that shorter pause durations will 
result in higher initiation rates. 
 Indeed, TT-seq analysis revealed that strongly paused genes have lower initiation 
frequencies. Furthermore the initiation frequency is lower when Cdk9-mediated pause 
release is inhibited, indicating that pausing directly delimits the transcription initiation 
rate. This is in line with a kinetic model of transcription, predicting that paused poly-
merases restricts further initiation events (Henriques et al. 2013) and might be explained 
by steric interference of paused Pol II which blocks initiation. Phosphorylation of Ser5 
by Cdk7 is a hallmark of transcription initiation. Studies of a Cdk7as cell line in combi-
nation with recombinant Cdk9as demonstrated that Cdk9 kinase activity and Cdk9-
dependent downstream events require proper initiation facilitated by Cdk7 (Larochelle 
et al. 2012). In conclusion, these results suggest that a basal initiation rate is a prerequi-
site for promoter proximal pausing which in return delimits further initiation events. 
This enables the cell to alter the synthesis rate of a given RNA by increasing or decreas-
ing the number of initiating polymerases. Moreover, pausing can promote initiation by 
keeping the promoter proximal region nucleosome-free (Gilchrist et al. 2010). 
 Abortive transcription during early elongation has been well described (reviewed in 
Shandilya & Roberts 2012). Furthermore, Pol II can also undergo premature termina-
tion within the gene body, as indicated by localization of decapping and termination 
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factors 500 bp downstream of the TSS (Brannan et al. 2012). However, if and how 
premature termination also occurs at the pause site has not been conclusively addressed 
yet. If this was the case, the levels of RNA transcribed from the region between TSS and 
pause site should be elevated for strongly paused genes. In the present work, less labeled 
RNA was observed in the short region between TSS and pause site for transcription 
units with long pause durations. This implies that paused Pol II does generally not ter-
minate, consistent with the finding that in the paused state, Pol II is stably engaged with 
the DNA template (reviewed in Adelman & Lis 2012).  
3.6 The combined actions of Brd4 and Cdk9 regulate the re-
lease of paused Pol II 
The present work highlights the importance of the P-TEFb-interacting domain of Brd4 
(see chapter 2.4.3). Thus, the function of Brd4 is linked to the pause release of Pol II 
which is facilitated by the kinase activity of Cdk9, the catalytic subunit of P-TEFb. Brd4 
recruits P-TEFb as response to various stimuli including serum stimulation, pro-
inflammatory signals, and disease signals such as in MLL (Dawson et al. 2011; 
Nicodeme et al. 2010; Zippo et al. 2009). These and other findings demonstrated that in 
addition to classical paused, immediate early genes like c-Myc, FOS or JUNB (Lu et al. 
2015), Brd4 regulates a diverse set of genes dependent on the cellular and environmental 
context (Liu et al. 2015). The potential of Brd4 to regulate cell-type specific events has 
been associated with so-called super enhancers. Super enhancers are highly active and 
can be differentiated from regular enhancers by high occupancy of Mediator subunit 
Med1 or Brd4 (Lovén et al. 2013). They regulate gene sets that typically define the iden-
tity of a cell, as it was demonstrated for many cell and tissue types including B-cells, em-
bryonic stem cells, heart and lung tissue (Hnisz et al. 2013). Thus, Brd4 is crucial for 
maintaining developmental integrity. Accordingly, it was demonstrated that Brd4 con-
trols the self-renewal ability and pluripotency of mESCs (Di Micco et al. 2014). Similar 
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results were obtained when investigating the distinct roles of Brd2 and Brd4 in adaptive 
immunity. Interestingly, Brd2 and Brd4 facilitate activation of genes essential for Th17 
cell development, emphasizing the ability of Brd4 to potentiate specific transcriptional 
programs (Cheung et al. 2017). 
 
 
Figure 3-2 | Transcription is regulated by Brd4-mediated recruitment of P-TEFb. Model of 
Pol II pause release. Pol II is blocked at the pause site by negative elongation factors NELF and 
DSIF. This limits further transcription initiation. The elongation block is released upon Cdk9-
dependent phosphorylation of NELF, DSIF, and Pol II CTD at Ser2. Subsequently the pause 
site is cleared, allowing further initiation events. Cdk9, the catalytic subunit of P-TEFb, is re-
cruited to active chromatin by the PID domain of Brd4, which binds to acetylated histone tales, 
using its two N-terminal bromodomains. This mechanism presumably occurs frequently at su-
per enhancers, where Brd4 promotes expression of cell-type specific genes (‘cell identity 
genes’) and tumor oncogenes. 
 
The supposed role of Brd4 as a master regulator of cell identity is intriguing. Indeed, 
I observed that > 50% of expressed genes were deregulated upon JQ1 treatment or ex-
pression of dnBrd4 mutants. This demonstrates that Brd4 regulates a substantial portion 
of actively transcribed genes. Positive correlation of Cdk9-sensitive genes with Brd4 oc-
cupancy further indicates that these genes are regulated by the combined action of Brd4 
and Cdk9. Strongly paused genes were enriched for higher order chromatin interac-
tions, that are formed e.g. by enhancers. Together, I propose a model in which Brd4 and 
Cdk9 together regulate transcription of genes whose expression has to be rapidly in-
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duced and tightly controlled (Figure 3-2). Promoter proximal pausing is the control 
mechanism that delimits transcription of the discussed genes. Presumably, the activity 
of Brd4 is governed by enhancers and super enhancers, which coordinate cell-specific 
expression patterns. 
3.7 Outlook 
The dominant-negative approach presented in this work has refined the roles of Brd4 
domains BD2 and PID in detail. However, additional dnBrd4 mutants should be ana-
lyzed on the transcriptome level, especially mutants that comprise other domains of 
Brd4 including BD1, ET, and BID/PDID. The non-bromodomain regions ET and 
BID/PDID are of particular interest, because our understanding of these domains is still 
very limited. Similarly the roles of the other BET members Brd2 and Brd3 can be eluci-
dated using dominant-negative mutants of Brd2 and Brd3. Transcriptome data of 
dnBrd2/3 mutants should be compared to the data obtained for dnBrd4 and JQ1 to un-
tangle the functional diversity of the BET protein family. 
The analog-sensitive Cdk9 cell line has proven a powerful tool to study the role of 
Cdk9 in transcription. Analog-sensitive kinases can further be used to identify the target 
proteins that are phosphorylated by an individual kinase using mass spectrometry. This 
has already be done in an in vitro approach for Cdk9as (Sansó et al. 2016). However, in 
this particular study, the assay was performed using whole cell extracts, thereby risking 
unspecific phosphorylation events that do not take place in vivo. Therefore, the Cdk9as 
cell line presented here should be used to study the phospho-proteome of Cdk9 in vivo 
to discover new target proteins and verify those that were identified before. 
Together with Roland Schüller, I have previously established a combined genetic and 
mass-spectrometric approach to measure heptad-specific phosphorylation of RNA 
Pol II CTD (Schüller et al. 2016). I plan to combine this strategy with specific inhibition 
of Cdk9as to identify and quantitate the Cdk9-specific target residues within the CTD. 
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In vivo this was not possible before, since conventional Cdk9 inhibitors such as Flavo-
piridol have off-target effects. Particularly, other CTD kinases are sensitive to Flavopiri-
dol as well. For a detailed comparison of all known Cdks that have putative CTD kinase 
activity (Cdk7, Cdk8, Cdk9, Cdk12, and Cdk13), CRISPR-engineered cell lines express-
ing analog-sensitive versions of these kinases should be constructed. Analysis of the 
transcriptome, phospho-proteome and CTD phosphorylation pattern in the analog-
sensitive cell lines will help to dissect the individual functions of the respective kinases. 
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4 Materials and Methods 
4.1 Material 
4.1.1 Chemicals 
1,4-Dithiothreitol (DTT)       Carl Roth GmbH&CoKG, Karlsruhe 
1 kb DNA ladder         Invitrogen, Karlsruhe 
1-NA-PP1           Calbiochem, Merck Millipore, Darmstadt 
4-thiouracil (4sU)        Sigma-Aldrich Chemie GmbH, München 
Agarose           Invitrogen, Karlsruhe 
Bromophenol blue (BPB)      Sigma-Aldrich Chemie GmbH, München 
Dimethyl sulfoxide (DMSO)      Sigma-Aldrich Chemie GmbH, München 
DMEM medium (Gibco)      Life Technologies, Eggenstein 
Doxycycline          Sigma-Aldrich Chemie GmbH, München 
DPBS (Gibco)          Life Technologies, Eggenstein 
Ethylendiaminetetraacetic acid (EDTA)  Carl Roth GmbH&CoKG, Karlsruhe 
Ethanol (EtOH), absolute      Merck, Darmstadt 
Ethidium bromide (EtBr)      Fluka Chemie GmbH, Buchs 
Fetal bovine serum (FBS)      PAA Laboratories, Pasching, Österreich 
Glycerol 86%          Carl Roth GmbH&CoKG, Karlsruhe 
Glycine           Carl Roth GmbH&CoKG, Karlsruhe 
HL-dsDNase          ArcticZymes, Tromsø, NO 
Hygromycin B         Amresco, Solon, OH, USA 
Isopropanol, absolute       Carl Roth, Karlsruhe 
L-glutamine 200mM (Gibco)     Life Technologies, Eggenstein 
Methanol (MeOH), absolute      Merck, Darmstadt 
Neomycin (G148)        Promega Corp., Wisconsin, USA 
Opti-MEM (Gibco)        Life Technologies, Eggenstein 
Orange G           Sigma-Aldrich Chemie GmbH, München 
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Penicillin/Streptomycin 10k U/ml (Gibco)  Life Technologies, Eggenstein 
Phenylmethanesulfonyl fluoride (PMSF)  ICN Biomed. Inc., Fountain Pkwy, USA 
Polyacrylamide 30% (PAA)      Carl Roth GmbH+Co.KG, Karlsruhe 
Powdered milk, blotting grade     Carl Roth GmbH+Co.KG, Karlsruhe 
Prestained Protein Ladder Plus     Fermentas, St. Leon-Rot 
QIAzol           Qiagen GmbH, Hilden 
RPMI medium 1640 (Gibco)     Life Technologies, Eggenstein 
Sodium dodecyl sulfate (SDS)     Carl Roth GmbH+Co.KG, Karlsruhe 
Tetramethylethylenediamine (TEMED)  Carl Roth GmbH+Co.KG, Karlsruhe 
Tetracycline          Promega Corp., Wisconsin, USA 
Tris(hydroxymethyl)aminomethane (TRIS) Merck, Darmstadt 
TRIzol            Thermo Fisher Scientific, Waltham 
Trypan blue          Invitrogen, Karlsruhe 
Tween-20           Sigma-Aldrich Chemie GmbH, München 
4.1.2 Consumables and kits 
AFAmicro tubes         Covaris Ltd., Brighton, UK 
Agar plates          Greiner GmbH, Frickenhausen 
Amaxa Mouse ES Cell Nucleofector Kit   Lonza, Köln 
Ampure XP beads        Beckman-Coulter, München 
CellTiter 96Aqueous one solution    Promega Corp., Wisconsin, USA 
Cover slides          Menzel, Braunschweig 
Cryovials 1.5 ml         Nunc GmbH, Wiesbaden 
Direct-zol kit          Zymo Research, Freiburg 
DNA Mini/Maxi kits        Qiagen GmbH, Hilden 
E-Plates 16-wells         OMNI Life Science, Bremen 
ECL detection reagent       GE healthcare, München 
Gene Pulser cuvettes        Bio-Rad Laboratories GmbH, München 
Gel blotting Paper GB003      Schleicher & Schuell, Deutschland 
Hybond N+ nylon membrane     GE Healthcare, München 
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KAPA HiFi DNA Polymerase     Kapa Biosystems, Wilmington, MA, USA 
Laboratory glassware        Duran Productions GmbH & Co. KG, Mainz 
mRNA-SENSE kit        Lexogen, Vienna, AT 
Nitrile gloves duoSHILD       SHIELD Scientific, Bennekom, NL 
NucleoSpin gel extraction kit     Macherey Nagel, Düren 
Ovation Universal RNA-Seq System   NuGEN, Leek, NL 
Parafilm           Carl GmbH+Co.KG, Karlsruhe 
Pasteur pipettes         Hirschmann Laborgeräte, Eberstadt 
Pipette tips ART 10, 20, 200, 1000    MolecularBio-Products, San Diego 
Plastic ware for cell culture      Greiner Bio-One, Frickenhausen 
Reaction tubes 1.5 ml, 2 ml      Eppendorf Deutschland, Wesseling-Berzdorf 
Reaction tubes 15 ml, 50 ml      Becton Dickinson Biosiences, Heidelberg 
RNA nano chip kit        Agilent Technologies, Waldbronn 
Scalpel            Braun, Tuttlingen 
Sterile filters          Merck Millipore, Darmstadt 
Streptavidin beads        Miltenyi Biotec, Bergisch Gladbach 
T4 DNA Ligase         New England Biolabs, Frankfurt a.M. 
4.1.3 Technical instruments 
-80°C freezer Hera Freeze      Thermo Fisher Scientific, Waltham 
-20°C freezer Eco Plus       Siemens, München 
AQUAline AL 12 waterbath      LAUDA, Lauda-Königshofen 
Bacteria shaker (Series 25)      New Brunswick ScientificCo., NJ, USA 
BioAnalyzer          Agilent Technologies, Waldbronn 
Bio-Rad PowerPac 300       Bio-Rad Laboratories GmbH, München 
Branson Sonifier 250        Heinemann Ultraschall- und Labortechnik 
Countess automated cell counter (Invitrogen) Thermo Fisher Scientific, Waltham 
Electrophoresis equipment      Bio-Rad Laboratories GmbH, München 
Electroporator (eukaryotic cells)    Bio-Rad Laboratories GmbH, München 
Eppendorf Centrifuge 5417R     Eppendorf Deutschland, Wesseling-Berzdorf 
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Eppendorf Thermomixer C      Eppendorf Deutschland, Wesseling-Berzdorf 
Fridge KU 1710 Vario       Liebherr, Biberach 
FACS Aria II flow cytometer     BD Biosciences, Heidelberg 
FACS Calibur flow cytometer     BD Biosciences, Heidelberg 
Focused ultrasonicator S220      Covaris Ltd, Brighton, UK 
Fuchs-Rosenthal chamber      GLW Gesellschaft für Laborbedarf GmbH 
Gilson Pipettes 2, 10, 20, 200,1000    Gilson, Bad Camberg 
Hypercassette          Amersham Biosciences, Freiburg 
Illumina HiAeq 1500        Illumina Inc., San Diego, CA, USA 
iMac 27-inch, Late 2013       Apple Inc., Cupertino, CA, USA 
Inkubator Heraeus 6000       Heraeus Sepatech GmbH, Osterode 
Incubator HERA cell 150      Heraeus Sepatech GmbH, Osterode 
Laminar Flow Hood        BDK Luft-und Reinraumtechnik GmbH 
Magnet stirrer M23        GLW, Würzburg 
Microwave NNV 689W       Panasonic, Hamburg 
Mighty Small Transphor Unit TE 22   GE Healthcare, München 
Mighty Small II SE260 Electrophoresis Unit Amersham Biosciences, Freiburg 
MiniSpin Plus centrifuge       Eppendorf Deutschland, Wesseling-Berzdorf 
Multi-calimatic pH-meter      Knick GmbH+Co.KG, Berlin 
Nanodrop 1000         Thermo Fisher Scientific, Waltham 
Odyssey imaging system       LI-COR Biosciences GmbH, Bad Homburg 
PipetMan P          Gilson, Bad Camberg 
Power supply Peqlab EV202      VWR Life Science, Erlangen 
Primo Vert light microscope      Carl Zeiss Jena GmbH, Göttingen 
Rollermixer SRT 6        Stuart Equipment, Staffordshire, UK 
Rotanta 460 R centrifuge       Hettich, Tuttlingen 
Rotina 380 centrifuge       Hettich, Tuttlingen 
Scanmaker i800 plus        Microtek, Taiwan 
Sunrise Photometer        Tecan Group Ltd., Männedorf, CH 
UV lamp Peqlab VL-4. LC      VWR Life Science, Erlangen 
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Vi-CELL XR cell counter      Beckman Coulter, München 
Vortexer Reax 2000        Heidolph Instruments GmbH, Schwabach 
xCELLigence RTCA DP       Roche Diagnostics, Mannheim 
4.1.4 Software 
Adobe Illustrotor CS6       Adobe Systems, Dublin, IRL 
Adobe Photoshop CS6       Adobe Systems, Dublin, IRL 
FlowJo 2 V.10.0.8r1        FlowJo LLC, Ashland, OR, USA 
Image J 2.0.0-rc-43/1.50g      Wayne Rasband, Maryland, MD, USA 
MacVector 14.5.2         MacVector Inc., Cambridge, UK 
Magellan v7.2          Tecan Group Ltd., Männedorf, CH 
Mendeley Desktop 1.17.6      Elsevier Inc., New York, NY, USA 
Microsoft Office 2010, 2011      Microsoft, Washington, DC, USA 
RTCA 2.0 Software (xCELLigence)    Roche Diagnostics, Mannheim 
UCSF Chimera 1.8.1        University of California (Pettersen et al. 2004) 
4.1.5 Buffers and solutions 
0.7% Agarose-TAE-Gel for DNA    2.1 g Agarose 
             300 mL 1x TAE 
             boil in microwave 
             cool to 65°C 
             EtBr (375 ng/µL) 
 
10 x DNA Loading Dye       20 g Sucrose 
             100 mg Orange G 
             add 50 mL H2O 
 
Laemmli-Buffer (2x)        2% SDS 
             100 mM DTT 
             10 mM EDTA 
             10% Glycerol 
Materials and Methods  72 
 
             60 mM Tris/HCl pH 6,8 
             0.01% BPB 
             1 mM PMSF 
 
LB-medium          20 mM MgSO4 
             10 mM KCl 
             1% Bacto-Tryptone 
             0.5% Bacto-yeast extract 
             0.5% NaCl 
 
LB-agar           20 mM MgSO4 
             10 mM KCl 
             1% Bacto-Tryptone 
             0.5% Bacto-yeast extract 
             0.5% NaCl 
             1.2% Bacto-agar 
 
Milk powder solution       5% powdered milk in 1 x TBST 
 
PBS            137 mM NaCl 
             2.7 mM KCl 
             4.3 mM Na2HPO4*6H2O 
             1.4 mM KH2PO4 
 
SDS-PAGE separating gel (6.5%)    4.3 mL PAA 30% 
             10 mL 2xTris/SDS pH 8.8 
             5.5 mL H2O 
             1167 µL APS 
             17 µL TEMED 
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SDS-PAGE separating gel (10.5%)    7 mL PAA 30% 
             10 mL 2xTris/SDS pH 8.8 
             2.8 mL H2O 
             167 µL APS 
             17 µL TEMED 
 
SDS-PAGE separating gel (12.5%)    8.3 mL PAA 30% 
             10 mL 2xTris/SDS pH 8.8 
             1.5 mL H2O 
             167 µL APS 
             17 µL TEMED 
 
SDS-PAGE stacking gel (4%)     2 mL PAA 30% 
             15 mL 2xTris/SDS pH 6.8 
             5.4 mL H2O 
             90 µL APS 
             20 µL TEMED 
 
SDS-PAGE-running buffer (10x)    60.4 g Tris/Base 
             288 g Glycin 
             5 ml SDS 20% 
             add 2 L H2O 
 
1x Tris acetate EDTA (TAE)      40 mM Tris Acetate 
             1 mM EDTA 
             adjust pH to pH 8.0 
 
1x Tris buffered saline (TBS)     10 mM NaCl 
             1 mM Tris/HCl pH 7.5 
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Tris EDTA (TE)         10 mM Tris 
             1 mM EDTA 
             adjust pH to 8.0 
 
2x Tris/SDS pH 6.8        7.56 g Tris/Base 
             2.5 mL SDS 20% 
             add 250 mL H2O 
             pH 6.8 (with HCL) 
 
2x Tris/SDS pH 8.8        22.68 g Tris/Base 
             2.5 mL SDS 20%  
             add 250 mL H2O 
             pH 8.8 (with HCL) 
 
Western-transfer buffer (10x)     60.4 g Tris/Base 
             288 g Glycin 
             5 mL SDS 20% 
             200 mL methanol 
             add 2 L H2O 
 
Western-blocking-reagent      10% (v/v) TBS 
             0.1% (v/v) Tween 20 
             5% (w/v) powdered milk  
4.1.6 Antibodies 
Primary antibodies  source      clone   species  usage 
anti α-Tubulin   Sigma (T9026)   T6557   mouse   WB 1:20,000 
anti Brd4     Bethyl (A301-985A)  polyclonal  rabbit   WB 1:10,000 
anti Cdk9     Santa Cruz (sc-484)  polyclonal  rabbit   WB 1:2,000 
anti Cdk12    Sanza Cruz (sc-81834) R12   mouse   WB 1:5,000 
anti CTD Ser2-P   Dr. E Kremmer   3E10   rat    WB 1:10 
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anti CTD Ser5-P   Dr. E Kremmer   3E8   rat    WB 1:10 
anti CTD Ser7-P   Dr. E Kremmer   4E12   rat    WB 1:10 
anti GAPDH    Dr. E Kremmer   5C4   rat    WB 1:5,000 
anti HA     Roche Diagnostics  3F10   rat    WB 1:20 
anti Rpb1     Dr. E. Kremmer   Pol3.3   mouse   WB 1:5 
 
Secondary antibodies    source           usage 
HRP anti mouse IgG     Promega          WB 1:5,000 
HRP anti rabbit IgG     Promega          WB 1:5,000 
HRP anti rat IgG+IgM    Jackson Laboratories       WB 1:5,000 
IRDye 800 anti mouse IgG   Rockland Inc.         WB 1:10,000 
Alexa Fluor 680 anti rat IgG   Invitrogen          WB 1:20,000 
4.1.7 Oligo nucleotides 
PCR primers   sequence (5’ to 3’)           modification 
BRD4 wt for   CCACCATGTCTGCGGAGAGCG        5’ phospho 
BRD4 f2 for   CCACCATGATGATAGTCCAGGCAAAAG           -||- 
BRD4 f3 for   CCACCATGACCACCATTGACCCCATTC           -||- 
BRD4 f4 for   CCACCATGGTCCGATTGATGTTCTCCAAC          -||- 
BRD4 f5 for   CCACCATGAAGCACAAAAGGAAAGAGGAAGTGG         -||- 
BRD4 f6 for   CCACCATGCACCATCATCACCACCATCAG          -||- 
BRD4 f7 for   CCACCATGACCCAAACACCCCTGCTC           -||- 
BRD4 f8 for   CCACCATGCACAAGTCGGACCCCTAC           -||- 
BRD4 f9 for3   CCACCATGGCCCCTGACAAGGACAAA           -||- 
BRD4 wt rev   GAAAAGATTTTCTTCAAATATTGAC            -||- 
BRD4 f1 NLS rev  TACCTTTCTCTTCTTTTTTGGCTGGGTCTGCGGAGGAG       -||- 
BRD4 f2 NLS rev  TACCTTTCTCTTCTTTTTTGGCTTCTTGGCAAACATCTC       -||- 
BRD4 f3 NLS rev  TACCTTTCTCTTCTTTTTTGGGCTATCGCTGCTGCTGTC       -||- 
BRD4 f4 NLS rev  TACCTTTCTCTTCTTTTTTGGCTTGTCCTCTTCCTCCGAC      -||- 
BRD4 f5 NLS rev  TACCTTTCTCTTCTTTTTTGGAATGAAGGGTGGGGGCGAGG      -||- 
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BRD4 f6 NLS rev  TACCTTTCTCTTCTTTTTTGGGGAAGGGAGTAGCGGCGT       -||- 
BRD4 f7 NLS rev2 TACCTTTCTCTTCTTTTTTGGCTCCTTCACCACCACGAAGG      -||- 
BRD4 f8 NLS rev  TACCTTTCTCTTCTTTTTTGGCTTCTCACGCTCCTCTTTC      -||- 
BRD4 wtNLS rev  TACCTTTCTCTTCTTTTTTGGGAAAAGATTTTCTTCAAATATTGAC-||- 
CDK9 for    CCACCATGGCAAAGCAGTACG             -||- 
CDK9 rev    GAAGACGCGCTCAAACTCC              -||- 
 
Seq. primers   sequence (5’ to 3’)  
BRD4 862 for   CAGCCTGTGAAGACAAAG 
BRD4 2300 for  CCAAACCGAAAGTCCAGGC 
BRD4 f5 for 387  CTATGTCACCTCCTGTTTGC 
BRD4 f7 rev 368  ATGTGGGTGGAAAACTGC 
BRD4 f7 rev 555  GGAATGTATCATAAGCGGG 
CDK9 screen for  CCCCGTAGCTGGTGCTTCCTCG 
CDK9 screen rev  CCCCAGCAGCCTTCATGTCCCTAT 
CMV profor   GGCGGTAGGCGTGTA 
hGH_rev    TATTAGGACAAGGCTGGTGGGCAC 
rgGlob-irv   AACAATCAAGGGTCCCC 
 
gRNA primers  sequence (5’ to 3’) 
CDK9 gRNA for  CACCGGCTCGCAGAAGTCGAACACC 
CDK9 gRNA rev  AAACGGTGTTCGACTTCTGCGAGCC 
 
CDK9 targeting donor oligo  sequence (5’ to 3’) 
AAAGTGTGTTGGGTGTGGTTTTCTTGACTTTTTCTTCTTTCTATTCCTGCCTCAGCTTC 
CCCCTATAACCGCTGCAAGGGTAGTATATACCTGGTcgcgGACTTCTGCGAGCATGACC 
TTGCTGGGCTGTTGAGCAATGTTTTGGTCAAGTTCACGCTGTCTGAGATCAAGAGGGTG 
ATGCAGATGCTGCTTAACGGCCT 
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4.1.8 Bacteria 
DH10B 
E.coli strain purchased from Invitrogen GmbH, Karlsruhe. Used for the cloning of all 
plasmid DNA, including the sub-cloning vector pSfi-Express and end-cloning vector 
pRTS-1. 
 
4.2 Methods 
4.2.1 Plasmids 
All plasmids (Table 4-1) were stored in TE buffer at -25°C. Sanger sequencing was per-
formed to verify the correct sequences of the expression cassettes (Sequiserve GmbH, 
Vaterstetten). The raw sequencing data was edited and aligned using the MacVector 
software in combination with the ClustalW alignment algorithm. All pRTS-1-based 
plasmids can be stably transfected in human cell lines Raji and H1299, where the vector 
is episomally maintained by the Epstein-Barr Virus (EBV) gene EBNA1. 
 
Table 4-1 | Plasmids used in this study. 
Name Backbone plasmid Resistance Reference 
wtBRD4-HA (1-1362) pRTS-1 Ampicilline Bornkamm et al. 2005 
f1-BRD4-HA (1-209) -||- -||- -||- 
f2-BRD4-HA (172-368) -||- -||- -||- 
f3-BRD4-HA (298-492) -||- -||- -||- 
f4-BRD4-HA (422-606) -||- -||- -||- 
f5-BRD4-HA (550-801) -||- -||- -||- 
f6-BRD4-HA (738-947) -||- -||- -||- 
f7-BRD4-HA (895-1112) -||- -||- -||- 
f8-BRD4-HA (1049-1239) -||- -||- -||- 
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f9-BRD4-HA (1174-1362) -||- -||- -||- 
f-BD1-BRD4-HA (54-168) -||- -||- -||- 
CDK9-HA -||- -||- -||- 
pFLAG-CMV2-BRD4 (1-1362) pFLAG-CMV2 -||- Bisgrove et al. 2007 
FLAG-CDK9 pFLAG-CMV2 -||- Wang et al. 2008 
pSpCas9-CDK9 gRNA-GFP PX458 -||- Ran et al. 2013 
 
4.2.2 Brd4 and Cdk9 cloning strategy 
HA-tagged Brd4 constructs were cloned into the pRTS-1 vector (Bornkamm et al. 2005; 
Hölzel et al. 2007). Nine different primer pairs were designed to amplify subfragments 
f-BD1 and f1-f9 of the BRD4 open reading frame (ORF) via polymerase chain reaction 
(PCR) with a pFLAG-CMV2-BRD4 (1-1362) plasmid as template DNA (Addgene 
#22304; Bisgrove et al. 2007). A CCACC Kozak sequence followed by a start codon, and 
a SV40 nuclear localization signal (PKKKRKV) were added during the PCR using the 
designed primers. A PCR product containing the full-length ORF of BRD4 was ampli-
fied in the same manner but lacking the NLS. 
Next, a C-terminal HA tag, STOP codon and two SfiI restriction sites that flanked 
the whole ORF were added via blunt-end ligation of the PCR product with sub-cloning 
construct pSfi-Express. After SfiI restriction digest the fragment was ligated with the 
pRTS-1 vector, which features a doxycycline-inducible, bidirectional promoter, also ex-
pressing eGFP (Figure 4-1). A pRTS-1 construct containing the luciferase gene served as 
vector control. HA-tagged Cdk9 was cloned in the same manner, using FLAG-CDK9 
(Addgene #28100; Wang et al. 2008) as template DNA for the initial PCR. 
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Figure 4-1 | Schematic vector map of the pRTS-1 wtBRD4-HA plasmid. An rtTA-responsive, 
bidirectional CMV promoter (biCMV) is flanked by eGFP and the gene of interest, here full-
length Brd4 followed by a C-terminal HA-tag. EBNA1, the EBV gene EBNA1; bla, β-lactamase 
gene conferring bacterial resistance to ampicilline; oriP, the bacterial origin of replication; hyg, 
the hygromycin phosphotransferase gene conferring eukaryotic resistance to hygromycine; 
rtTA, tetracycline controlled transcriptional activator; tetTS, tetracycline-controlled transcrip-
tional silencer (Bornkamm et al. 2005). 
4.2.3 Ligation of DNA constructs 
For ligation, the PCR or restriction digest product was first purified via agarose gel elec-
trophoreses and extracted using the NucleoSpin gel extraction and PCR purification kit 
(Macherey Nagel) according to the manufacturer’s protocol. The purified DNA frag-
ment was diluted in H2O, mixed with the linear vector DNA, incubated at 50°C for 5 
min and immediately stored on ice. Then T4 ligase buffer and T4 DNA ligase were add-
ed and the mixture was incubated at 16°C over night (o/n).  
4.2.4 Construction of analog-sensitive Cdk9 Raji cells 
Analog-sensitive Cdk9 Raji cells were constructed by Weihua Qin (AG Leonhardt, LMU 
Munich) as described before (Mulholland et al. 2015) with slight modifications. The 
amino acid sequence of the Cdk9 kinase domain (UniProt, P50750-1) was aligned with 
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the sequence of the kinase domains of well-studied kinases to identify the gatekeeper 
residue of Cdk9 (F103; Table 4-2) (Lopez et al. 2014). 
 
Table 4-2 | Sequence alignment of selected domains. Selected kinase domains were 
aligned to identify the gatekeeper residue (highlighted in orange) of Cdk9 (F103). Se-
quences of the kinase domains were retrieved from the UniProt database (The UniProt 
Consortium 2017) and sequence alignment was performed using the Clustal Omega 1.2.4 
online tool (Sievers et al. 2011). * fully conserved residue; : strong conservation; . weak conser-
vation 
 
 
Next, the guide RNA (gRNA) for guiding Cas9 to targeting site was designed using 
the optimized CRISPR Design tool available online at http://crispr.mit.edu/ (Zhang Lab 
MIT, 2015). The gRNA was cloned into the px458 backbone, which then expressed both 
gRNA and GFP-Cas9 (Addgene #48138; Ran et al. 2013). A single strand (ss) DNA oligo 
carrying an F to A mutation was synthesized and served as targeting donor to replace 
the gatekeeper residue F to A, thereby producing a BstUI cleavage site (Figure 4-2A). 
The gRNA and donor DNA were mixed 1:1 and transfected into Raji cells using the 
amaxa mouse ES cell nucleofector kit (Lonza). After two days of expression, GFP-
positive cells were sorted into 96 well plates (12×) by means of FACS (Becton Dikinson). 
Survival clones were collected and genomic DNA was isolated for PCR screening. The 
targeting region was amplified by PCR and the PCR product was digested with BstUI to 
identify positive clones (Figure 4-2B). Finally, positively selected clones were verified by 
sequencing. 
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Figure 4-2 | Construction of analog-sensitive Cdk9as (F103A) using CRISPR/Cas9. 
(A) A ssDNA oligo served as donor to replace the gatekeeper residue F to A, which further 
introduced a BstUI restriction site. (B) The targeting region of survival clones was amplified with 
screening (sc) primers and the PCR product digested with BstUI. The digested DNA was de-
tected in an agarose gel. CRISPR/Cas9 targeting of Cdk9 was carried out by Weihua Qin 
(Leonhardt group, LMU Munich).  
 
4.2.5 Bacterial cell culture 
4.2.5.1 Transformation of competent cells 
Competent DH10B bacteria cells were transformed by mixing 50 µL of DH10B either 
with the whole ligation product or with 5 µg of purified plasmid DNA, followed by in-
cubation for 20 min on ice. Next, a heat shock was performed for 30 s at 42°C and the 
cells were directly put on ice for 2 min. 400 µL LB medium were added and the cells 
were incubated at 37°C. After 90 min the cells were plated on selective agar plates. The 
plates were stored at 37°C o/n. 
4.2.5.2 Miniprep of bacterial plasmid DNA 
On the next day multiple clones were picked for o/n miniculture for which the clones 
were incubated in LB medium (2 mL total miniculture volume each). The miniculture 
was followed by miniprep, which started with the centrifugation of 1.5 ml miniculture 
(16,400 rpm; 4°C; 1 min), resuspension of the cell pellet in 150 µL buffer P1 and incuba-
tion at RT for 5 min. Buffer P1, P2 and P3 were taken from the QIAGEN Plasmid Maxi 
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kit but an alternate protocol was used. The cells were then lysed by adding 150 µL buffer 
P2 followed by mixing and 5 min incubation at RT. Next, 150 µL of cold buffer P3 was 
added to neutralize the lysate which was then mixed and incubated on ice. After 30 min 
the samples were centrifuged (16,400 rpm; 4°C; 5 min) and the SN was transferred into 
a new 1.5 mL microcentrifuge tube. The SN was mixed with 450 µL isopropanol, incu-
bated for 5 min, and again centrifuged (16,400 rpm; 4°C; 5 min). The resulting pellet 
was washed with 1 mL 70% ethanol and after drying it for 5 min on air it was resus-
pended in 200 µL H2O. 
4.2.5.3 Maxiprep of bacterial plasmid DNA 
Maxiculture was set up by inoculating 400 mL LB medium (50 µg/mL kanamycin) with 
500 µL of the miniculture of chosen clones. All maxipreps were performed using the 
QIAGEN Plasmid Maxiprep kit. Briefly, the o/n maxiculture was harvested by cetrifug-
ing at 3600 rpm for 15 min at 4°C. The bacterial pellet was resuspended in 10 mL buffer 
P1. Subsequently, 10 mL of buffer P2 were added to the resuspended cells and mixed 
thoroughly by inverting 10 times. After 5 min incubation 10 mL of prechilled buffer P3 
were added and the mixture was inverted again. Next the suspension was centrifuged for 
30 min at 4,000 rpm at 4°C. Meanwhile, a QIAGEN tip was equilibrated by applying 
10 mL buffer QBT and allowing the column empty by gravity flow. Next, the super-
natent of the mixture was applied to the tip and the flow-through was discarded. The tip 
was washed twice with 30 mL wash buffer QC. The DNA was eluted by adding 15 mL 
elution buffer QF and the eluted DNA was collected in a fresh 50 mL vessel. 10.5 mL 
isopropanol were added and centrifuged at 4,000 rpm for 30 min at 4°C. The superna-
tant was discarded and 5 mL 70% ethanol were added and centrifuged at 4,000 rpm at 
4°C to wash the DNA pellet. The supernatant was decanted and the pellet was air-dried 
for 10 min. Finally the DNA was collected by resuspending in 300 µL TE buffer. 
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4.2.6 Human cell culture 
4.2.6.1 Cell lines 
Raji 
This EBV-positive B-cell line was established from the left maxilla of a 12 year-old Afri-
can boy with Burkitt’s lymphoma in 1963 (Pulvertaft 1964). Identity of Raji cells (DSMZ 
no.: ACC 319) was verified by determining genetic characteristics using PCR-single-
locus-technology (Eurofins Genomics). Raji cells harbor a t(8;14) translocation that 
places the c-Myc gene into the highly active immunoglobulin locus, leading to overex-
pression of the oncogene (Taub et al. 1984). 
 
H1299 
The non-small cell lung cancer cell line H1299 (ATCC-no.: CRL-5803) was established 
from a metastatic site of a lung lymph node of a 43 years Caucasian male. The cells grow 
adherent and display an epithelial morphology. Genetically, H1299 cells have a homo-
zygous partial deletion of the TP53 gene, thus lacking expression of the p53 protein 
(Bodner et al. 1992). 
4.2.6.2 Cell culture conditions 
Cells were cultured in RPMI (Raji) or DMEM (H1299) supplemented with 10 % fetal 
calf serum, 2 mM L-glutamine, and 1% penicillin streptomycin at 37°C, 5 % CO2 (Raji) 
or 8 % CO2 (H1299). 
4.2.6.3 Stable transfection of Raji and H1299 cells 
Raji and H1299 cells were stably transfected using Qiagen PolyFect in combination with 
Opti-MEM medium. To this end, 6 µg of plasmid DNA and 16 µL PolyFect solution 
were diluted in 400 µL Opti-MEM each. After 5 min the two solutions were mixed and 
incubated for 30 min at RT. Meanwhile the cells were washed once with PBS and cov-
ered with 8 mL Opti-MEM. Next the transfection mix was added to the cells, followed 
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by 7 h 30 min incubation at 37°C. Then, the Opti-MEM medium was replaced by stand-
ard growth medium supplemented with 100 µM hygromycin B for 1 week, which was 
increased to 200 µM for 3 additional weeks. Expression of recombinant proteins was 
induced by adding 25 ng/mL or 1,000 ng/mL doxycycline to Raji or H1299 cell culture 
medium, respectively. These concentrations were determined for each cell line individu-
ally, because doxycycline itself caused proliferation defects when used at high concentra-
tions.  
4.2.7 Cell proliferation assays 
Cell culture density was measured using different systems. Proliferation of H1299 cells 
was monitored via the xCELLigence system. Triplicates of H1299 cells were seeded in 
16-well E-Plates at a density of 5,000 cells per well and the cell index was monitored. 
After 24 h cells were induced with doxycycline (1 µg/mL) or treated with JQ1 (1 µM) 
and the cell index was compared with non-treated cells for additional 48 h. 
Because the xCELLigence system cannot be applied to suspension cells, a Vi-CELL 
XR cell counter was used to measure proliferation of Raji cells transfected with Brd4 
constructs. The long-term impact of JQ1 on Raji cells was detected with a Countess au-
tomated cell counter. For this, cells were mixed with an equal amount of 0.4% trypan 
blue solution and applied to counting chamber slides which were inserted into the 
Countess cell counter. 
Cell proliferation at increasing JQ1 or 1-NA-PP1 concentrations was assessed 
using the CellTiter 96 AQueous One Solution Cell Proliferation Assay System. Cells 
were seeded in duplicates in a 96-well plate and increasing concentrations of JQ1/1-NA-
PP1 or DMSO (control) were added. After 72 h MTS tetrazolium compound was added 
to each well for one hour. Then the quantity of the MTS formazan product was meas-
ured as absorbance at 490 nm with a Sunrise photometer which was operated using the 
Magellan data analysis software. Relative signals were calculated by dividing the JQ1/1-
NA-PP1 signals by the corresponding DMSO signals. 
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4.2.8 Flow cytometry 
The bi-directional promoter of the pRTS-1 vector drives expression of eGFP in addition 
to the inserted construct. This allows for quantification of the positively transfected, 
eGFP-positive cell population by means of flow cytometry. Raji cells were washed, re-
suspended in phosphate buffered saline (PBS), and submitted to an XCalibur flow cy-
tometer. For data acquisition, non-induced cells were gated for lymphocytes from which 
the eGFP-negative gate was defined for the following measurements. FlowJo 2 software 
was used for data analysis. 
4.2.9 Western analysis 
Cells were lysed in 2x laemmli buffer, boiled at 95 °C for 5 min, and sonified (10 pulses, 
output 5, duty cycle 50%) before submission to discontinuous sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). SDS-PAGE was run at 30 mA constant 
per gel for about 2 h. Next, transfer to nitrocellulose membrane was prepared using the 
wet blot principle. The separating gel was laid onto one wet layer whatman paper and 
the water-soaked membrane was carefully applied onto the gel. After placing a final slice 
of whatman paper on top, the stack was taken into a transfer chamber filled with trans-
fer buffer and eventually transfer was started (450 mA constant; 1.5 h). 
Prior to primary antibody incubation, unspecific binding of antibodies was blocked 
by 1 h incubation of the membrane with 5% milk (w/v) in Tris-buffered saline plus 1% 
Tween (TBS-T). Blocking was followed by primary Ab incubation at 4°C o/n. The 
membrane was washed three times in TBS-T for 5 min before the secondary Ab was 
added. The membrane was incubated with HRP-conjugated secondary antibodies. Im-
portantly, the membrane was washed three times in TBST and rinsed once in H2O prior 
to detection. The signals were visualized via enhanced chemiluminescence using the 
Amersham ECL Western Blotting Detection Reagent. For this, equal amounts of ECL 
substrate reagents A and B were mixed and 1 ml of this mixture was spread onto the 
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membrane. ECL signals were captured by exposing film to the membrane. This last step 
was performed in the dark room where the films were also developed. 
Alternatively, fluorophor-coupled secondary antibodies were used and incubated for 
1.5 h at room temperature. After washing, these blots were visualized using the Odyssey 
system (Licor). This allows for multiplexing of two different secondary antibodies, be-
cause the emitted fluorescence differs in wavelength (anti mouse: 680 nm; anti rat: 
800 nm). Signals were measured by scanning the TBS-T-soaked membrane with the 
Odyssey scanner, producing digital images as a result. 
4.2.10 Poly(A) RNA-seq library preparation 
24 hours after induction/JQ1 treatment, cells were washed twice in DPBS, resuspended 
in TRIzol reagent and short-term stored at -80 °C until library preparation. Library 
preparation and RNA sequencing was done in collaboration with Stefan Krebs from the 
LAFUGA group of Helmut Blum at the Gene Center (LMU Munich). Total RNA was 
isolated using the Direct-zol kit. The quality of total RNA was controlled using a 
nanodrop ND1000 photospectrometer: The ratios of absorbance at 260 nm and 280 nm 
ranged from 1.93 to 1.97 and 260/230 ratios ranged from 2.1 to 2.2. RNA integrity was 
checked on an Agilent BioAnalyzer 2100 with the Agilent RNA nano chip kit: RNA in-
tegrity numbers (RIN) ranged from 9.7 to 10 (scale 1 to 10; 10 for highest quality).  
Next 1 µg of total RNA was used for preparation of Illumina-compatible strand-
specific cDNA (RNA-seq) libraries using the mRNA-SENSE kit from Lexogen. Briefly, 
polyA RNA was bound to oligo dT beads; starter and stopper heterodimer oligos were 
annealed to captured mRNA. Starter oligos served as primer for cDNA synthesis which 
continued until stopper. Stopped cDNA and stopper were ligated to yield a cDNA frag-
ment flanked by Illumina P5 and P7 sequences. This was followed by PCR amplifica-
tion, which introduced barcodes and adaptor sequences to the libraries. PCR products 
were purified with Ampure XP beads, followed by quantification and quality control 
with Agilent BioAnalyzer 2100 using a DNA 1000 chip. Samples were sequenced on Il-
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lumina HiSeq 1500 in single end mode with 76 bp read length and i7 index read. The 
sequencing depth was ~ 2x107 reads per sample. 
4.2.11 Bioinformatics analysis of Brd4/JQ1 RNA-seq data 
Bioinformatics analysis was performed by Michael Kluge from the research group of 
Caroline Friedel at the Institute for Informatics (LMU Munich) as described in Decker 
et al. 2017. After trimming adapters from sequencing reads using cutadapt (Martin 
2011), reads were mapped to the human reference genome GRCh38 as well as rRNA 
sequences using ContextMap 2 (Bonfert et al. 2015). Read counts per gene were deter-
mined using featureCounts (Liao et al. 2014) on the Ensembl gene annotation (release 
84). Reads were assigned to a gene if they overlapped with an exon of the gene by at least 
25 bp and mapped uniquely to that gene. ~ 80% of reads could be mapped per sample. 
Genes were included in downstream analyses if the average read count across all sam-
ples was ≥ 25 (~ 11,700 genes). 
Before gene expression analysis, principal component analysis (PCA) and hierar-
chical clustering of samples were performed. For PCA, read counts were normalized 
using limma (Smyth 2005). Hierarchical clustering analysis was based on the Euclidean 
distances between the normalized read counts. Differential expression analysis for each 
condition against the control was performed with limma, edgeR and DESeq2 (Love et al. 
2014; Robinson et al. 2010). Multiple testing correction was performed using the Ben-
jamini–Hochberg method (Benjamini & Hochberg 1995). Genes were selected for fur-
ther analysis if they were identified as differentially expressed by at least two of the three 
methods (multiple testing corrected p-value ≤ 0.05, Supplementary Table 1).  
4.2.12 Transient transcriptome sequencing (TT-seq) of Cdk9as cells 
TT-seq experiments were performed essentially as described before in Schwalb et al. 
2016 together with Saskia Gressel from the group of Patrick Cramer (MPI for Biophysi-
cal Chemistry, Göttingen). Two independent biological replicates were prepared. Brief-
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ly, for TT-seq experiments, 3.3 x 107 Raji B cells were treated for 15 minutes with solvent 
(DMSO) or 5 µM of 4-Amino-1-tert-butyl-3-(1’-naphthyl)pyrazolo[3,4-d]pyrimidine 
(1-NA-PP1). Labeling was performed with the addition of 500 µM of 4-thiouracil (4sU) 
for 5 min at 37 °C and 5 % CO2. Cells were harvested by centrifugation at 3,000 x g for 2 
min. Total RNA was extracted using QIAzol according to the manufacturer’s instruc-
tions. RNAs were sonicated to generate fragments of <1.5 kb using AFAmicro tubes in a 
Covaris S220 Focused-ultrasonicator. 4sU-labeled RNA was purified from 150 µg total 
fragmented RNA. Following thiol-specific biotinylation, labeled RNA was separated 
using streptavidin beads. Prior to library preparation, 4sU-labeled RNA was purified 
and quantified. Enrichment of 4sU-labeled RNA was analyzed by RT-qPCR as described 
before in (Schwalb et al. 2016). Input RNA was treated with HL-dsDNase and used for 
strand-specific library preparation according to the Ovation Universal RNA-Seq Sys-
tem. The size-selected and pre-amplified fragments were analyzed on a Fragment Ana-
lyzer before clustering and sequencing on the Illumina HiSeq 1500. 
4.2.13 Bioinformatics analysis of TT-seq data 
Bioinformatics analysis of the TT-seq data was performed by Björn Schwalb (Cramer 
group) as described recently (Gressel et al. 2017). Briefly, baired-end 50 base reads with 
additional 6 base reads of barcodes were obtained for each of the samples, i.e. 2 repli-
cates of TT-Seq with 1-NA-PP1 treatment and 2 replicates of TT-Seq with DMSO 
treatment. Reads were demultiplexed and mapped with STAR 2.3.0 (Dobin et al. 2013) 
to the hg20/hg38 (GRCh38) genome assembly (Human Genome Reference Consorti-
um). Quality filtering of SAM files was performed using Samtools (Li et al. 2009). Here 
alignments with MAPQ smaller than 7 (-q 7) were skipped and only proper pairs (-f99, -
f147, -f83, -f163) were selected. Further data processing was carried out using the 
R/Bioconductor environment. 
Spike-in (RNAs) normalization strategy was used essentially as described before in 
(Schwalb et al. 2016) to allow observation of global shifts and antisense bias determina-
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tion (ratio of spurious reads originating from the opposite strand introduced by the RT 
reactions) in TT-seq signal. Read counts for all spike-ins were calculated using HTSeq 
(Anders et al. 2015). Sequencing depth calculations resulted in no detectable global dif-
ferences. For each annotated gene, transcription units (TUs) were defined as the union 
of all existing inherent transcript isoforms (UCSC RefSeq GRCh38). Read counts for all 
features were calculated using HTSeq (Anders et al. 2015) and corrected for antisense 
bias. Read counts per kilobase (RPK) were calculated upon bias corrected read counts 
falling into the region of a transcribed unit divided by its length in kilobases. 
Calculation of the number of transcribed bases: For each sample aligned duplicated 
fragments were discarded. Of the resulting unique fragment isoforms only those were 
kept that exhibited a positive inner mate distance. The number of transcribed bases (tbj) 
for all samples was calculated as the sum of the coverage of evident (sequenced) frag-
ment parts (read pairs only) for all fragments with an inner mate interval not entirely 
overlapping a Refseq annotated intron (UCSC RefSeq GRCh38, ~ 98% of all fragments) 
in addition to the sum of the coverage of non-evident fragment parts (entire fragment). 
Calculation of response ratios. For each condition (DMSO or 1-NA-PP1) the anti-
sense bias corrected number of transcribed bases was calculated for all expressed TUs 
exceeding 10 kb in length. Of all remaining TUs only those were kept harboring one 
unique TSS based on all Refseq annotated isoforms (UCSC RefSeq GRCh38). Response 
ratios were calculated for a window from the TSS to 10 kb downstream for each TU. 
Estimation of elongation velocity. For each condition TUs exceeding 35 kb in length 
were used and truncated by 5 kb as described above. Of all remaining TUs only those 
were kept harboring one unique TSS given all Refseq annotated isoforms (UCSC RefSeq 
GRCh38). For each TU the elongation velocity [kb/min] was calculated, given that the 
difference of transcribed bases obtained by the 1-NA-PP1 treatment equals the number 
of transcribed bases per nucleotide times the number of nucleotides traveled, corrected 
by the amount of the response. 
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Determination of pause site. For all expressed TUs exceeding 10 kb in length with 
one unique TSS given all Refseq annotated isoforms (UCSC RefSeq GRCh38) the pause 
site was calculated in a window from TSS to 500 bases for all non-negative mNET-seq 
coverage values (Nojima et al. 2015). 
For estimation of (productive) initiation frequency (pause release rate) all expressed 
TUs exceeding 10 kb in length and harboring one unique TSS were used. For each TU 
the (productive) initiation frequency [cell-1min-1] was calculated based on the labeling 
duration of 5 min and the length of the TU. Note that analysis was restricted to regions 
of non-first constitutive exons (exonic bases common to all isoforms). 
Pause durations were calculated for all expressed TUs exceeding 10 kb in length with 
one unique TSS. The pause duration di [min] was calculated as the residing time of the 
polymerase in a window +/- 100 bases around the pause site (see above). Pause duration 
di was derived from the pause release rate and the number of polymerases (mNET-seq 
coverage values, Nojima et al. 2015) in a window +/- 100 bases around the pause site. 
For pause sites below 100 bp downstream of the TSS the first 200 bp of the TU were 
considered.  
Ehrensberger inequality. The inequality from (Ehrensberger et al. 2013) states that 
new initiation events into productive elongation are limited by the velocity of the poly-
merase in the promoter-proximal region and the footprint of the polymerase on the 
DNA template (50 bp). 
 
Table 4-3 | External datasets used for analysis. 
Experiment Factor Cell type GEO ID Source Authors 
DNase Hi-C  K562 GSE56869 Nat Methods 2015 Ma, Duan 
mNET-seq Pol II Hela S3 GSE60358  Cell 2015 Nojima, Proudfoot 
ChIP-seq NELF-E K562 GSE31477 ENCODE 2011 Struhl 
ChIP-seq CDK9 HEK293T GSE51633 Cell 2013 Liu, Rosenfeld 
ChIP-seq CDK9 HCT116 GSE70408 Cell 2015 Chen, Shilatifard 
ChIP-seq Brd4 HEK293T GSE51633 Cell 2013 Liu, Rosenfeld 
ChIP-seq Brd4 Hela GSE51633 Cell 2013 Liu, Rosenfeld 
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